lab_id,phase,PatientId,consensus_sex,inferred_sex,inferred_ethnicity,centerID,CEBPA_Biallelic,ageAtDiagnosis,isRelapse,isDenovo,isTransformed,finalFusion,specificDxAtAcquisition_MDSMPN,nonAML_MDSMPN_specificDxAtAcquisition,priorMalignancyNonMyeloid,priorMalignancyType,cumulativeChemo,priorMalignancyRadiationTx,priorMDS,priorMDSMoreThanTwoMths,priorMDSMPN,priorMDSMPNMoreThanTwoMths,priorMPN,priorMPNMoreThanTwoMths,dxAtInclusion,specificDxAtInclusion,ELN2017,ELN2008,dxAtSpecimenAcquisition,specificDxAtAcquisition,ageAtSpecimenAcquisition,timeOfSampleCollectionRelativeToInclusion,specimenGroups,specimenType,rnaSeq,exomeSeq,totalDrug,rnaSeqAnalysis,analysisExomeSeq,analysisDrug,cumulativeTreatmentTypeCount,cumulativeTreatmentTypes,cumulativeTreatmentRegimenCount,cumulativeTreatmentRegimens,cumulativeTreatmentStageCount,cumulativeTreatmentStages,responseToInductionTx,typeInductionTx,responseDurationToInductionTx,mostRecentTreatmentType,currentRegimen,currentStage,mostRecentTreatmentDuration,vitalStatus,overallSurvival,causeOfDeath,any_different_labs,any_different_labs_also_beataml,different_lab_ids,different_id_karyotype_interval,%.Basophils.in.PB,%.Blasts.in.BM,%.Blasts.in.PB,%.Eosinophils.in.PB,%.Immature.Granulocytes.in.PB,%.Lymphocytes.in.PB,%.Monocytes.in.PB,%.Neutrophils.in.PB,%.Nucleated.RBCs.in.PB,ALT,AST,Albumin,Creatinine,FAB/Blast.Morphology,Hematocrit,Hemoglobin,Karyotype,LDH,MCV,Other.Cytogenetics,Platelet.Count,Surface.Antigens.(Immunohistochemical.Stains),Total.Protein,WBC.Count,any_different_cgs,any_different_cgs_also_beataml,different_cgs_lab_ids,FLT3-ITD,NPM1,ABL1,ASXL1,ASXL2,ATM,BCOR,BCORL1,BRAF,BRCA2,CALR,CBL,CCND2,CCND3,CD36,CEBPA,CHEK2,CIITA,CREBBP,CSF3R,CTCF,CUX1,DNMT3A,EP300,ETV6,EZH2,FBXW7,FLT3,GATA1,GATA2,IDH1,IDH2,IKZF1,JAK1,JAK2,JAK3,KDM6A,KIT,KMT2A,KMT2D,KRAS,MEN1,MPL,MUTYH,MYD88,NF1,NOTCH1,NRAS,PAX5,PDGFRB,PHF6,POT1,PRDM1,PTPN11,RAD21,ROS1,RUNX1,SETBP1,SF3B1,SMC1A,SOCS1,SRSF2,STAG2,STAT3,SUZ12,TCL1A,TET2,TP53,TYK2,U2AF1,WT1,ZRSR2
13-00098,training,1011,Female,Female,Black,2,n,64,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Induction,5,Unknown,,"",FALSE,FALSE,"",0,1.4,76,0,0.1,,94.3,1.5,2.7,,22,20,3.6,0.48,"",32.6,10.9,"46,XX[14]",184,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],",32,"CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+)",7.5,1.5,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00118,training,685,Male,Male,White,1,n,54,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,57,349,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,7,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",5,Consolidation|Salvage|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Decitabine,Re-induction,160,Dead,1378,Dead-Disease,TRUE,FALSE,12-00109,-349,3,71,83,2,,5,10,4,,35,31,3.9,0.81,M4,33.7,11.7,"47,XY,+21[15]/46,XY[5]",438,100.6,Trisomy 21,119,"CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123",7.1,33.8,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00149,training,1049,Male,Female,White,1,n,78,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Bladder Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,79,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Induction,-1,Dead,267,Dead-Disease,FALSE,FALSE,"",0,0,87,72,1,,17,4,1,,19,41,3.4,0.75,"",32.3,10.6,"45,X,-Y[19]/46,XY[1]",460,103.6,Normal,15,"CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +",6.2,8.5,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",1031?1032 ins AAC; MAF 50%,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",p.R369R; MAF 50%,""
13-00157,training,1054,Female,Female,White,1,n,60,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,104,Alive,1379,Alive,FALSE,FALSE,"",0,0,80,32,0,,11,13,23,,32,50,2.9,0.64,"",41.1,13.4,"46,XX[20]",660,86.1,normal,228,"partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive",7.4,53.9,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","","","","","",p.Q696fs*9; MAF 40%,"","","","",negative,"","",p.R132H; MAF 40%,"","","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","",p.G503A; MAF 40%,"","",negative,"","","","","","","","","","",negative,"","",negative,""
13-00160,training,967,Male,Male,White,1,n,70,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73,93,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|Azacitidine",2,Induction|Maintenance,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Azacitidine,Maintenance,-1,Dead,1165,Dead-Unknown,TRUE,FALSE,13-00049,-93,,"","",,,,,,,"",,,,"",,,"46,XY[19]",,,Normal,,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00163,leaderboard,1058,Male,Male,HispNative,1,n,24,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,24,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide",4,Allogeneic - Sibling|Consolidation|Unknown|Induction,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,400,Alive,FALSE,FALSE,"",0,0,50,6,0,,19,52,16,,"",,,,M4,26.3,9.2,"47,XY,inv(16)(p13q22),+22[20]",,91.5,inv(16),53,"- 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO",,13.8,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",p.D816H; MAF ~50%,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",rs16754; MAF ~50%,""
13-00165,training,1060,Female,Female,White,3,n,33,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,33,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)",4,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Dead,439,Dead-Treatment,FALSE,FALSE,"",-2,,"","",,,,,,,"",,,,"",,,"46,XX[7]",,,"",,"",,,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00166,training,1061,Male,Male,White,1,n,65,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,67,0,Post-Chemotherapy|Residual Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,8,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine",6,Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Cladribine,Unknown,5,Dead,1020,Dead-Unknown,FALSE,FALSE,"",0,0,"",77,0,,15,1,3,,18,10,3.6,1.01,M2,28.1,9.3,"",132,93.5,"",22,"",6.3,19.5,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00186,training,1072,Male,Male,White,1,n,74,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",n,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Dead,126,Dead-Unknown,FALSE,FALSE,"",0,0,60,29,1,,26,18,24,,250,160,3.2,0.59,"",22,7.1,"46,XY[20]",399,87.4,"",107,"partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive",7,11.8,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",p.A142Gfs*4; MAF 30%,"","","","",p.P95L; MAF 48%,"","","","","",negative,"","",negative,""
13-00195,training,1078,Male,Male,White,1,n,66,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,66,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,74,Alive,972,Alive,FALSE,FALSE,"",0,0,90,24,0,,14,61,1,,19,14,2.4,1.13,M5,23.9,7.9,"46,XY[20]",387,103.6,normal,122,"CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive",6.3,28,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","",p.Q2208H; MAF 50%,"","","",p.R882H; MAF 50%,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",rs16754; MAF 50%,""
13-00204,training,1088,Female,Female,White,1,n,65,FALSE,TRUE,FALSE,PML-RARA,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)",1,Induction,Unknown,Standard Chemotherapy,5,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,3,Dead,7,Dead-Other,FALSE,FALSE,"",0,0,72,57,0,,36,1,8,,24,33,2.9,0.6,M3,20.7,6.8,"46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3]",398,90.2,"Unusual t(15;17), with the fusion signal on the derivative chromosome 15",10,"partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive",5.6,9.8,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","",negative,"",p.K66N; MAF 40%,"","","","","","","","",negative,"","",rs16754; MAF 50%,""
13-00226,training,928,Female,Female,White,1,n,83,FALSE,FALSE,TRUE,PML-RARA,FALSE,FALSE,n,"",y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,83,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"ATRA, Arsenic Trioxide|Idarubicin",2,Induction|Symptom Control,Complete Response,Standard Chemotherapy,253,Standard Chemotherapy,Idarubicin,Symptom Control,0,Alive,1429,Alive,FALSE,FALSE,"",0,0,75,2.1,0,,17,2,23,,14,9,3.7,0.7,M3,23.4,8.1,"46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5]",367,86.2,16q deletion,,"CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive",6.8,6,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",D835H; MAF Unlisted,"","",negative,"","","",p.V617F; MAF 90%,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","","",""
13-00232,leaderboard,1101,Female,Female,White,1,n,22,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,22,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Matched Unrelated Donor,-1,Alive,1001,Alive,FALSE,FALSE,"",0,0,55,29,2,,7,33,24,,67,16,2.2,0.64,M4,24,8,"46,XX[24]",373,95.2,normal,34,"CD7, CD13, CD33, CD34, CD38, CD56, partial CD64,     CD117,        dim CD123, HLA-DR and MPO+",6.5,29.4,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",p.D107fs*; MAF ~50%,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",rs16754; MAF ~50%,""
13-00245,training,1108,Male,Male,Asian,1,n,8,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,8,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",2,Induction|Intensification,Complete Response,Standard Chemotherapy,11,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Intensification,62,Alive,857,Alive,FALSE,FALSE,"",0,0,30,17,0,,33,17,20,,"",,,0.53,M2,29.3,10.3,"46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]",,93.5,t(8;21),109,"dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO",,19.5,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00262,training,1118,Female,Female,White,2,n,64,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,21,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,124,Dead,455,Dead-Disease,FALSE,FALSE,"",-1,,81,94,,,6,,,,87,47,2.8,0.53,"",27.2,9.7,"46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]",743,,"nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",11,"CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +).",5.2,26,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00281,training,1131,Female,Female,White,4,n,79,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Azacitidine, Lenalidomide",1,Salvage,"","",,Standard Chemotherapy,"Azacitidine, Lenalidomide",Salvage,137,Dead,189,Dead-Disease,FALSE,FALSE,"",0,,73,56,,,,1,,,"",,,,"",,,"46,XX,del(16)(p11.2)[3]/46,XX[2]",,,"",,"CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR",,8.7,FALSE,FALSE,"",negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,R140Q,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
13-00331,training,1153,Female,Female,White,4,n,35,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,37,1,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI",5,Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,53,Dead,761,Dead-Treatment,FALSE,FALSE,"",0,,92,97,,,,,,,"",,,,M5,,,"46,XX[5]",,,"",,"CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR",,140,FALSE,FALSE,"",negative,positive,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",D835,"","",positive,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
13-00353,training,1161,Female,Female,Asian,1,n,30,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,30,0,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,31,Dead,270,Dead-Disease,FALSE,FALSE,"",0,0,64,65,0,,28.9,25.4,19.3,1.7,48,33,3.6,0.64,"",21.8,7.5,"46,XX,t(9;11)(p11;q34)[19]/46,XX[1]",,111.8,Disruption of MLL signal and t(9;11),29,"CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive",6.1,29.25,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","",p.T910S; MAF 40%,"","","",negative,"","","","",p.D835; MAF 35%,"","",negative,"","","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","",negative,""
13-00354,training,1163,Male,Male,Asian,4,n,73,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,73,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG)",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Stanford Protocol 9153 (TLI, ATG)",Allogeneic - Mismatched Unrelated Donor,-1,Dead,330,Dead-Other,FALSE,FALSE,"",0,,84,71,,,,6,,,"",,,,"",,,"46,XY[20]",,,"",,""""" CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO""""",,16.2,FALSE,FALSE,"",negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
13-00365,leaderboard,1171,Female,Female,White,4,n,72,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine, Lenalidomide|Temozolomide, Vorinostat",2,Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"Temozolomide, Vorinostat",Re-induction,-1,Dead,420,Dead-Unknown,TRUE,FALSE,13-00366,-13,,"","",,,,,,,"",,,,"",,,"46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]",,,"",,"",,,TRUE,FALSE,13-00366,positive,positive,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",positive,"","","",""
13-00393,leaderboard,1184,Male,Male,HispNative,2,n,52,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,52,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG",5,Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,15,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1,Dead,1237,Dead-Disease,FALSE,FALSE,"",0,,21,5,,,68,4,23,,17,23,3.6,0.89,"",28.3,8.5,"89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]",183,,"nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]",22,"partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO",7.5,3.42,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00396,training,1187,Male,Male,White,1,n,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Consolidation,-1,Dead,228,Dead-Treatment,FALSE,FALSE,"",-2,1.8,51,3.5,0.9,,41.2,37.7,11.4,0,20,20,3.2,1.37,M4,33.7,11,"42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]",,92.6,Extra MLL signal,24,"CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR.",7.1,5.23,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","",negative,"","","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","","","","","","","","","","","","",p.R273S; MAF 40%,"","",negative,""
13-00406,training,1190,Male,Male,White,1,n,62,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,62,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Dead,2,Dead-Disease,FALSE,FALSE,"",0,0,95,66.3,0,,9.5,1.9,4.8,0.2,93,104,3.2,1.85,M5,26.2,8.5,"46,XY[20]",2941,104.8,Normal,92,"CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive",6.5,250.23,TRUE,TRUE,13-00409,positive,negative,"","","","","","","","","","","","","",negative,"","","","","","",p. R882C; MAF 50%,"","","","",negative,"","",negative,"","","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","Intron 5, 3' splice site mutation; MAF 50%","","","","","","","","","","",negative,"","","",""
13-00420,training,1194,Male,Male,White,2,n,75,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",4,Consolidation|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Maintenance,34,Dead,383,Dead-Disease,FALSE,FALSE,"",-98,,"","",,,,,,,"",,,,"",,,"47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5]",,,"nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200]",,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00425,training,1197,Female,Female,White,2,n,40,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,40,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,5,Alive,486,Alive,FALSE,FALSE,"",-1,,84,29,,,63,3,5,,21,23,3.7,0.65,"",35,12,"46,XX,t(9;11)(p22;q23)[20]",613,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",34,"brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR",6.5,9.1,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00450,training,1224,Female,Female,White,2,n,79,TRUE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,79,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"7+3 (Cytarabine, Idarubicin)|Crenolanib",2,Induction|Experimental,Complete Response,Standard Chemotherapy,4,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,14,Dead,124,Dead-Disease,FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"",,,"",,"",,,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00454,leaderboard,1226,Female,Female,HispNative,2,n,31,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,31,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,95,Unknown,,"",FALSE,FALSE,"",0,,"",45,3,,25,20,7,,"",,,1.04,"",22,7.4,"46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]",229,,"nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[200],(CBFBx2)(5’CBFB sep 3’CBFBx1)[147/200]",30,"CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-), MPO(+), TdT(partial +)",,13.63,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00468,training,1233,Male,Male,White,1,n,61,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Salvage,126,Dead,370,Dead-Disease,FALSE,FALSE,"",0,,17,10,,,27.7,,39.2,,47,22,3.8,0.5,"",25.8,8.5,"47~49,XY,-21,+1~4mar[cp21]/46,XY[2]",,86.6,Monosomy 21,40,"CD13, CD33, CD34. CD45, subset CD64, CD79a, CD117,HLA-DR, and subset TdT positive).",7.6,5.5,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","",p.T618I; MAF 50%,"","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",benign SNP rs16754 (R369R: no amino acid change); MAF 50%,""
13-00487,training,1243,Female,Female,White,1,n,35,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,35,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,94,Alive,358,Alive,FALSE,FALSE,"",0,0,49.4,28.6,1.8,,19.6,37.5,7.1,0,20,17,3.1,0.88,M4,14.3,4.8,"46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4]",505,100.7,Trisomy 22,36,"Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive.",7.8,49.4,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","",P552S; MAF 50%,"","","","","","","","",negative,"","",negative,negative,"","",negative,"",K395N; MAF 50%,D816V; MAF 1%,"","",negative,"",negative,"","","","",G13D; MAF 6%,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
13-00500,training,1248,Male,Male,White,2,n,71,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,"","",,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,55,Dead,156,Dead-Unknown,FALSE,FALSE,"",0,0,76,58,2,,38,6,14,,27,25,3.1,,"",25,8.5,"46,XY",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",93,"CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial +), HLA-DR(+), TdT(partial +), MPO(-)",5.8,7.5,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00513,training,1255,Male,Male,White,1,n,55,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,4,Dead,246,Dead-Disease,FALSE,FALSE,"",-274,1.4,75,"",8.5,,11.4,8.5,34,0.2,62,31,3.8,1.44,M5,38.1,12.2,"46,XY,t(9;11)(p22;q23)[20]",497,87.6,MLL rearrangement and t(9;11),32,"",7.9,10.21,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00515,training,1257,Male,Male,White,2,n,73,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),7,"Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)",6,Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,39,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,33,Dead,658,Dead-Unknown,FALSE,FALSE,"",0,1,32,67,2,,8,3,14,,15,30,4.1,,"",32.8,11,"46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18]",,,"18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",90,"CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-)",5.8,24.2,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00545,training,1286,Male,Male,White,4,n,71,FALSE,FALSE,FALSE,GATA2-MECOM,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,72,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,555,Dead-Disease,TRUE,TRUE,13-00546,2,,"","",,,,,,,"",,,,"",,,"45,XY,-7,t(3;3)[20]",,,"",,"",,,TRUE,TRUE,13-00546,positive,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",D835,"","",negative,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
13-00551,leaderboard,1314,Male,Male,Black,2,n,51,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",51,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,1487,Alive,FALSE,FALSE,"",-3,,"",1.0,,,17,35,23,,16,14,3.7,0.8,"",25,8.7,"46,XY[20]",,83.8,"",16,"",6.8,3.2,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00552,leaderboard,1315,Male,Male,White,3,n,74,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,75,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone",3,Hypomethylating/Low Dose Cytarabine|Salvage|Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,-1,Dead,415,Dead-Disease,FALSE,FALSE,"",-7,,"","",,,,,,,"",,,,"",,,"46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]",,,"normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22",,"",,,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00557,training,1233,Male,Male,White,1,n,61,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,43,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Salvage,126,Dead,370,Dead-Disease,FALSE,FALSE,"",0,,17,2,,,32.2,,34.2,,34,15,3.7,0.3,"",32.4,10.4,"46~49,XY,-21,+1~4mar[cp20]",,87.2,Monosomy 21,21,"CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, HLA-DR and partial TdT positive; aberrant monocytic population: CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive.",7,7.2,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00558,training,1341,Male,Male,White,1,n,61,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide",5,Allogeneic - Sibling|Salvage|Induction|Re-induction|Symptom Control,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Dead,213,Dead-Treatment,FALSE,FALSE,"",0,0,25,20,13,,6,12,55,0.9,45,34,3.1,0.8,"",31.1,9.8,"42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,",,88.9,Monosomy 5,243,"CD13, CD33, CD34, CD117, and MPO+.",6.4,96.64,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00573,training,1349,Male,Male,White,1,n,85,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,86,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,"","",,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,169,Dead,333,Dead-Disease,FALSE,FALSE,"",0,0,"","",0,,17,44,39,0,15,9,3.5,0.9,"",25.7,8.2,"",175,88,"",18,"",6.9,13.22,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00578,training,1353,Female,Female,White,2,n,30,FALSE,FALSE,FALSE,DEK-NUP214,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,31,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib",3,Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,52,Dead,568,Dead-Disease,TRUE,TRUE,13-00581,3,,"",47,,,,,,,49,31,4.2,0.85,"",,,"47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]",329,,"",10,"",6.3,20.2,TRUE,TRUE,13-00581,positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",D835,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00593,training,1257,Male,Male,White,2,n,73,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,37,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),7,"Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)",6,Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,39,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,33,Dead,658,Dead-Unknown,FALSE,FALSE,"",0,6,66,40,2,,19,20,8,,22,36,4.3,,"",34.7,11.6,"46,XY",,,"nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]",67,"CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +)",6.2,13.9,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00601,leaderboard,1369,Male,Male,White,2,n,,FALSE,FALSE,FALSE,None,TRUE,FALSE,n,"",y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,Intermediate,"",MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,,4,Unknown,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Unknown,Standard Chemotherapy,60,Standard Chemotherapy,Decitabine,Induction,60,Dead,116,Dead-Unknown,FALSE,FALSE,"",-3,,"","",,,,,,,"",,,,"",,,"46,XY[20]",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","",""
13-00602,training,1370,Male,Male,White,2,y,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,1433,Alive,FALSE,FALSE,"",-2,,"",85,0,,9,3,3,,16,27,2.9,0.75,"",,,"46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2].",682,,"nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200]",,"",6.6,33,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00615,training,1375,Female,Male,HispNative,4,n,62,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,62,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Induction,-1,Alive,239,Alive,FALSE,FALSE,"",0,,52,57,,,,6,,,"",,,,"",,,"46,XY,t(8;21)(q22;q22)[14]",,,"",,"CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO",,12.9,FALSE,FALSE,"",negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","","","","","","","",negative,"","","","","","",positive,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
13-00650,training,2737,Male,Male,White,7,n,,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,20,2,Unknown,Peripheral Blood,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Unknown,,"",FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"",,,"",,"",,,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00655,training,1394,Male,Male,White,3,n,62,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,62,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin) ",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, TBI",Allogeneic - Matched Unrelated Donor,-1,Dead,979,Dead-Disease,TRUE,TRUE,13-00654,-1,,93,58,,,,,,,"",,,,M5a,,,"47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]",,,8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present,,"Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.",,14.66,TRUE,TRUE,13-00654,negative,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
13-00658,training,1396,Male,Male,White,1,n,60,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,114,Alive,201,Alive,FALSE,FALSE,"",0,0.8,30,42.4,4.5,,19.7,8.3,15.9,0.3,49,23,3.5,1.22,"",30.6,10.6,"46,XY[21]",536,95.6,Normal,141,"CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive",7.2,11.93,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%,"","","","","","",negative,"","","","",p.I836delI; MAF 25%,"","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
14-00015,leaderboard,1161,Female,Female,Asian,1,n,30,TRUE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,31,147,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,31,Dead,270,Dead-Disease,FALSE,FALSE,"",0,0,75,35,0,,9.9,9.9,37.2,0.8,37,39,3.1,0.56,"",22.1,7.7,"46,XX,t(9;11)(p22;q23)[20]/46,XX[1]",,89.8,MLL disruption and t(9;11),39,"dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive",6,43.72,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",MAF 70%,"","","","","","",negative,"","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00021,training,1408,Male,Male,White,4,n,74,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,4,"Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924",4,Salvage|Induction|Re-induction|Symptom Control,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Salvage,-1,Dead,357,Dead-Disease,TRUE,FALSE,14-00022,-49,,"","",,,,,,,"",,,,"",,,"46,XY",,,"",,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00034,training,1431,Male,Male,White,1,y,55,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,906,Alive,FALSE,FALSE,"",0,0,50,25,0,,45.3,19.6,9.3,6,27,20,3.7,1.01,"",30.6,10.1,"46,XY[20]",,98.4,Normal,15,"CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO",6.3,3.85,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50%,"","","","","","","","","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","","","",negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","","","",negative,""
14-00041,training,1434,Female,Female,White,4,n,71,FALSE,TRUE,FALSE,GATA2-MECOM,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,71,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,AG-221,1,Hypomethylating/Low Dose Cytarabine,"","",,Standard Chemotherapy,AG-221,Hypomethylating/Low Dose Cytarabine,-1,Alive,952,Alive,TRUE,FALSE,14-00042,0,,22,8,,,,10,,,"",,,,M4,,,"46,XX,inv(3)?(q21q25)[21]",,,"",,"CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR",,2.6,TRUE,FALSE,14-00042,negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,positive,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00083,training,1989,Male,Male,White,4,n,46,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46,0,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,5,"HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine",4,Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Salvage,-1,Unknown,,"",FALSE,FALSE,"",-2,,"","",,,,,,,"",,,,"",,,"46,XY[20]",,,"",,"",,,FALSE,FALSE,"",negative,positive,"","","","","","",negative,"","","","","","",negative,"","","","","","",positive,"","","","",negative,"","",positive,negative,"","","","","",negative,"","",negative,"","","","","","",positive,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00092,training,1461,Female,Female,White,1,n,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,566,Alive,FALSE,FALSE,"",0,1.7,13,14,0.8,,9.4,28.2,49.6,1.6,18,26,2.8,0.74,M4,21.2,7.3,"46,XX[20]",514,101.4,Normal,57,"CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive",6.1,63.75,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","",p.V319I; MAF 50%,"","","",p.T138I; MAF 50%,"","","","","","","",negative,negative,"","","","","","","","",negative,"","","","","","",p.Q61H; MAF 40%,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00126,training,1451,Male,Male,White,3,n,46,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",Intermediate,Not Enough Information,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",46,14,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Alive,0,Alive,FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"",,,"",,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00127,training,1481,Male,Male,White,1,n,37,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,38,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,2,"7+3 (Cytarabine, Idarubicin)|Azacitidine",2,Induction|Maintenance,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Azacitidine,Maintenance,-1,Dead,207,Dead-Disease,FALSE,FALSE,"",-1,0,"",95,0,,0.9,0,0,0.1,17,56,1.8,0.6,"",23,7.9,"48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl",,86.8,Extra chromosome 5,20,"CD10, CD13, CD33, CD34, CD56 and HLA-DR positive",5.3,38.47,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","","p.G13D, MAF 46%","","","","","","","","",negative,"","","","","","","","","","","p.R273H, MAF 96%","","",negative,""
14-00135,training,1485,Male,Male,White,1,n,72,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Azacitidine|Decitabine,3,Consolidation|Induction|Maintenance,Unknown,Standard Chemotherapy,38,Standard Chemotherapy,Azacitidine,Maintenance,36,Dead,252,Dead-Disease,FALSE,FALSE,"",0,0,55,46,0,,27.8,27,20.6,0,32,31,2.2,1.37,M4,20.6,6.6,"43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]",435,85.8,Previous FISH results were consistent with the deleted 5q and trisomy 9,33,"CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+",5.9,20.82,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",p.H193R; MAF 92%,"","",negative,""
14-00141,training,1488,Male,Male,Asian,4,n,85,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,85,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Decitabine, Midostaurin",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,-1,Dead,357,Dead-Disease,TRUE,FALSE,14-00142,-15,,"","",,,,,,,"",,,,"",,,"46,XY[14]",,,"",,"",,,TRUE,FALSE,14-00142,negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00193,training,1519,Male,Male,White,2,n,56,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,57,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,3,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,3,Dead,421,Dead-Disease,FALSE,FALSE,"",0,0,"",54,0,,38,8,0,,15,23,3,1.3,"",,,"46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]",409,,"nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]",,"",6.6,8.2,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",Q61H; MAF 5%,"","","","","","","","","","","","","","","","","","","","","","","",""
14-00228,training,1532,Female,Female,White,1,n,46,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Azacitidine,Consolidation,339,Alive,788,Alive,FALSE,FALSE,"",0,0,80,45,1.6,,9.9,14.9,10.7,0,52,28,2.5,0.77,M4,25.2,8.4,"46,XX[20]",550,88.1,Normal,107,"dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+",6.3,57.23,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","","","","","",p.R882C; MAF 46%,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","",p.E76Q; MAF 40%,"","",negative,"","","","","","","","","","",negative,"","",negative,""
14-00240,leaderboard,1540,Female,Female,Black,2,n,78,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,78,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,n,y,y,1,Other,1,Azacitidine,1,Supportive/Palliative Care,"","",,Other,Azacitidine,Supportive/Palliative Care,-1,Dead,37,Dead-Disease,FALSE,FALSE,"",-17,,"",1,,,6,49,35,,9,15,2.9,1.09,"",26.1,8.3,"45,XX,+i(5)(p10),psudic(12;5)(p13;q11.2),-16,del(17)(p11.2p13)[5]/44,idem,-i(5)[3]/46,XX[12]",342,,"nuc ish(D5S721x2,D5S23x2,EGR1x1)[57/200]/(D5S721x4,D5S23x4,EGR1x1)[29/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[83/200]",50,"",6.7,51.64,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00259,leaderboard,1546,Female,Female,White,1,n,65,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC",4,Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Fludarabine,Consolidation,4,Dead,439,Dead-Disease,FALSE,FALSE,"",0,0.1,70,"",0.1,1.7,8.3,85.2,4.6,0.2,16,13,2.7,0.87,M4,30.4,9.6,"46,XX[20]",506,101.7,Normal,112,"CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive",7.4,58.86,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","",negative,"","","","","","",p.R882H; MAF 50%,"","","","",negative;MAF 12%,"","",negative,"","","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","",p.F71L; MAF 14%,"","",negative,"","","","","","","","","","",negative,"","",negative,""
14-00279,training,1558,Female,Female,HispNative,4,n,52,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,52,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,SWOG S1203 (7+3 +/- Vorinostat),1,Induction,Complete Response,Standard Chemotherapy,8,Standard Chemotherapy,SWOG S1203 (7+3 +/- Vorinostat),Induction,8,Alive,36,Alive,FALSE,FALSE,"",0,,91,79,,,,0,,,"",,,,"",,,"46,XX,inv(16)(p13.1q22)[cp20]",,,"",,"CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO",,28.1,FALSE,FALSE,"",negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","","","","","","",negative,"","",negative,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00289,training,1561,Male,Male,White,1,n,23,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,mediastinum mass,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,23,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) ",3,Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,8,Targeted Therapy - Kinase Inhibitor(s),Trametinib,Experimental,197,Dead,318,Dead-Disease,TRUE,FALSE,14-00288,0,3.2,3,20.4,2.1,,25.8,1.1,36.6,43.4,32,131,3,0.91,"",17.9,5.7,"48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]",16499,95.2,Low-level tetraploidy or near-tetraploidy,24,"",5.6,40.76,FALSE,FALSE,"",negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",p.G12C; MAF 86%,"","","","","","","","","","","","","","","","","","","",p.G245S; MAF 87%,"","","",""
14-00359,training,1604,Male,Male,White,3,n,58,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,58,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) ",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,210,Alive,761,Alive,TRUE,FALSE,14-00360,-2,,"","",,,,,,,"",,,,"",,,"48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2]",,,8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present,,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00376,leaderboard,1614,Male,Male,White,1,n,48,FALSE,FALSE,FALSE,None,TRUE,FALSE,n,"",y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,Intermediate,"",MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,48,0,Unknown,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Decitabine|Busulfan, Cyclophosphamide",2,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,116,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,714,Alive,FALSE,FALSE,"",0,0,17,5.3,0,,67.3,22.1,5.3,0,36,20,3.5,0.82,"",32.5,10.2,"47,XY,+8[18]/46,XY[2]",155,83.5,Trisomy 8,105,"CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+",7.9,0.94,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",p.R882C; MAF 45%,"","","","",negative,"","",p.R132C; MAF 44%,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","","","","","","","","","","",negative,"","","","","","","","","",p.P455R; MAF 45%,negative,"","",negative,""
14-00423,training,1644,Female,Female,White,4,n,51,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,51,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7,Bone Marrow Transplant,Stanford Protocol 9022 (BU/CY),Allogeneic - Matched Unrelated Donor,-1,Alive,795,Alive,TRUE,FALSE,14-00422,0,,74,61,,,,1,,,"",,,,M4eo,,,"46,XX,inv(16)(p13q22)[20]",,,"",,"CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT",,34.4,TRUE,FALSE,14-00422,negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","","","","","","",negative,"","",negative,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00434,training,1648,Female,Female,White,4,n,69,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,69,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Hydroxyurea,1,Induction,Unknown,Standard Chemotherapy,365,Standard Chemotherapy,Hydroxyurea,Induction,365,Alive,0,Alive,FALSE,FALSE,"",0,,94,83,,,,0,,,"",,,,M5a,,,"46,XX[1]",,,"",,"CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117",,137.6,FALSE,FALSE,"",negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","","","","","","",negative,"","",negative,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00448,leaderboard,1656,Female,Female,White,4,n,78,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Uterine Sarcoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,78,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Azacitidine, MLN4924",1,Induction,Refractory,Standard Chemotherapy,111,Standard Chemotherapy,"Azacitidine, MLN4924",Induction,111,Dead,161,Dead-Disease,TRUE,TRUE,14-00449,0,,78,77,,,,1,,,"",,,,"",,,"46,XX[20]",,,"",,"CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR",,5.6,TRUE,TRUE,14-00449,negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","","","","","","",negative,"","",positive,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00464,leaderboard,1664,Female,Female,White,4,n,22,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,22,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4,"ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)",4,Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,7,Bone Marrow Transplant,"Cyclophosphamide, TBI",Allogeneic - Matched Unrelated Donor,-1,Alive,453,Alive,FALSE,FALSE,"",0,,65,90,,,,0.1,,,"",,,,M1,,,"46,XX,t(9;11)(p22;q23)[22]",,,"",,"CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO",,40.2,FALSE,FALSE,"",negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","","","","","","",D835,"","",negative,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00495,leaderboard,1246,Male,Male,White,2,n,62,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64,254,Post-Chemotherapy|Post-Transplant|Residual Disease,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide",5,Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,141,Dead,568,Dead-Unknown,FALSE,FALSE,"",-28,,"","",,,,,,,23,26,2.9,,"",27.9,9.6,"45,XY,der(12;16)(q10;p10)[2]/46,XY[18]",,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]",30,"",5,27.4,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","",P203S; MAF unlisted,"","",T367fs*15; MAF unlisted,"","","","","",R882H; MAF unlisted,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00504,leaderboard,1693,Male,Male,White,2,n,35,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,35,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide, Thymoglobulin",Allogeneic - Matched Unrelated Donor,-1,Alive,1226,Alive,FALSE,FALSE,"",-2,,"","",,,,,,,"",,,,"",,,"46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]",,,"nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]",,"",,,FALSE,FALSE,"",positive,positive,"",D943fs*6; MAF 25%,"","","","","","","","","","","",negative,"","","","","","","","","","","",D835,"","",negative,negative,"","","","","","",MLL-AF9 fusion,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00514,training,1696,Male,Male,White,2,n,71,FALSE,FALSE,TRUE,Unknown,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71,0,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,"","",,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,107,Dead,53,Dead-Disease,FALSE,FALSE,"",0,0,"",50,1,,17,1,13,,19,42,3.2,1.83,"",23.7,7.7,"",766,92.2,"",11,"",7.1,45.6,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00537,leaderboard,1708,Male,Male,HispNative,2,n,17,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",17,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,n,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Bu/Cy/ATG|ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC + Midostaurin|Etoposide, Cytarabine",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Unknown,Standard Chemotherapy,-1,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1,Alive,74,Alive,FALSE,FALSE,"",-3,,"","",,,,,,,"",,,,"",,,"46,XY,t(11;19)(q23;p13.1)[19]/46,XY[1]",,,"",,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00559,training,1721,Male,Male,White,2,n,68,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Maintenance,-1,Alive,976,Alive,FALSE,FALSE,"",0,0,79,54,,,10,42,30,,8,26,4,,"",20.8,6.8,"46,XY",,,IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted,61,"CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-)",7.1,41.4,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","","","","","",R882C; MAF 50%,"","","","",negative,"","",negative,negative,"","","","","","","","","","","","","","","",G13D; MAF 44%,"","","","","","","","","","","","","","","","","","","","","","","",""
14-00567,training,1723,Female,Female,White,1,n,71,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Mismatched Unrelated Donor,-1,Dead,462,Dead-Treatment,FALSE,FALSE,"",-3,0,"","",0,0,6.7,5.1,0,0.1,20,20,2.6,0.62,M5,21.4,7,"46,XX,idic(7)(q11.2)[20]",373,93.9,"",19,"CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive",5.8,78.71,FALSE,FALSE,"",negative,negative,"","","","",p.T870fs*46 (2 bp deletion); MAF 50%,"","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",p.R132C; MAF 50%,negative,"","",negative,"","",negative,PTD,"",negative,"","","","","","",negative,"","","","","",p.S502L; MAF 50%,"","","","","","","","","","","","","",negative,"","","",""
14-00578,training,1730,Male,Male,White,1,n,75,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,IntermediateOrAdverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,75,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, TBI",Allogeneic - Mismatched Unrelated Donor,-1,Dead,327,Dead-Disease,FALSE,FALSE,"",0,0,90,"",0,0,6,2.6,0,0.1,18,49,2.6,0.94,M5,26.8,9.1,"46,XY[20]",1173,105.5,Normal,45,"dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive",6.8,98.9,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","",negative,"","","","","","",p.P777L; MAF 50%,"","","","",negative,"","",negative,p.R140Q; MAF 45%,"","",negative,"","",negative,PTD; no MAF available,"",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","",Intron 1 splice site (at invariant AG splice donor); MAF 90%,""
14-00581,training,1731,Female,Female,Black,4,n,68,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,68,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,CPX-351 (Liposomal Cytarabine + Daunorubicin),1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,CPX-351 (Liposomal Cytarabine + Daunorubicin),Induction,-1,Dead,70,Dead-Disease,TRUE,FALSE,14-00580,-1,,33,37,,,,8,,,"",,,,"",,,"42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]",,,"",,"CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO",,29.1,TRUE,FALSE,14-00580,negative,negative,"","","","","","",negative,"","","","","","",Triple positive,"","","","","","","","","","","",negative,"","",negative,positive,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00608,training,1749,Female,Female,White,4,n,75,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,77,716,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,"","",,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,1131,Dead,1134,Dead-Other,FALSE,FALSE,"",-710,,"","",,,,,,,"",,,,"",,,"46,XX[8]",,,"",,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00613,training,1752,Male,Male,White,2,n,31,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,31,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,5,Unknown,,"",FALSE,FALSE,"",-1,,80,56,2,,17,21,3,,63,39,3.9,0.91,"",28.8,10.2,"46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13]",434,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5’CBFB sep 3’CBFBx1)[164/200]",34,"CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variably +), HLA-DR(partial +), MPO(+), TdT(few +).",8.2,41.35,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00618,training,1754,Male,Male,White,2,n,77,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Lung Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,78,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine",4,Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Unknown,,"",FALSE,FALSE,"",0,,73,84,,,10,,6,,9,13,4.2,0.82,"",,,"46,XY[20]",165,,"",,"",6.5,13.8,FALSE,FALSE,"",negative,negative,"","","",S1993fs*23; MAF 44%,"","","","","","","","","",L81fs*72; MAF 92%,"","","","","","","","","","","","","","",negative,negative,"","","","","","","","","","","",G382D; MAF 49%,"","","","","","","","","","","","","","","","","","",R1205*; MAF 92%,"","","",M823fs*1; MAF 47%,"","","","",""
14-00643,training,1763,Male,Male,Asian,1,n,37,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,37,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide",4,Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,0,Alive,566,Alive,FALSE,FALSE,"",0,0.8,"","",0,7.5,17.5,0,37.5,0.4,22,13,3,0.89,M2,15.8,5.5,"45,X,-Y,t(8;21)(q22;q22)[20]",411,100.6,"RUNX1T1/RUNX1:   94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.",42,"dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive",7,8.15,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","",p.F445fs*3; MAF 30%,"",negative,"","",negative,negative,"","",negative,"","",p.Y418_D419insFL (exon 8); MAF 29%     ;p.N822K (exon 17); MAF 5%,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","",p.G1160E; MAF 49%,negative,"","","",""
14-00658,training,1775,Female,Female,White,3,n,59,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Azacitidine, Sorafenib",Hypomethylating/Low Dose Cytarabine,-1,Dead,254,Dead-Disease,FALSE,FALSE,"",-1,,51.5,72,,,,,,,"",,,,"",,,"46,XX[20]",,,Normal,,"Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.",,89.17,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00670,leaderboard,1787,Male,Male,Black,2,n,63,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,3,"AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG",3,Hypomethylating/Low Dose Cytarabine|Experimental|Allogeneic - Child,"","",,Bone Marrow Transplant,"Fludarabine, Melphalan, TBI, ATG",Allogeneic - Child,-1,Alive,1059,Alive,FALSE,FALSE,"",0,0,20,0,0,,76,0,24,,18,16,4.1,1.24,"",24.9,8.3,"46,XY[20]",148,100.4,"",72,"",7.4,1.8,FALSE,FALSE,"",negative,negative,"",G646fs*12; MAF 30%,"","","","","","","","","","",Y325*; MAF 46%,"","",Q320fs*41; MAF 51%,"","","",P442fs*16; MAF 38%,"","","","","","","","",negative,R140Q; MAF 46%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",P95H; MAF 40%,R614*; MAF 90%,"","","","","","","","",""
14-00672,leaderboard,1786,Male,Male,White,7,n,64,FALSE,FALSE,FALSE,None,TRUE,FALSE,n,"",y,n,n,n,n,n,y,n,MYELOPROLIFERATIVE NEOPLASMS,Essential thrombocythaemia,Intermediate,"",MYELOPROLIFERATIVE NEOPLASMS,Essential thrombocythaemia,77,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,Ruxolitinib|Imatinib|Hydroxyurea,2,Induction|Re-induction,Refractory,Standard Chemotherapy,4626,Standard Chemotherapy,Ruxolitinib,Re-induction,-1,Alive,5305,Alive,FALSE,FALSE,"",0,,15,"",,,,,,,"",,,,"",,,"47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1]",,,Nineteen of twenty metaphase cells examined had an extra derivative chromosome composed of a chromosome 1 long arm and a chromosome 9 short arm; two of these cells were in the tetraploid state with two copies of the derivative chromosome.,,"dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00676,training,1561,Male,Male,White,1,n,23,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,mediastinum mass,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,24,163,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) ",3,Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,8,Targeted Therapy - Kinase Inhibitor(s),Trametinib,Experimental,197,Dead,318,Dead-Disease,TRUE,TRUE,14-00289,0,0,5,10,0,2.9,36.2,1.5,47.8,,30,146,3.4,0.82,"",25.5,7.9,"48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]",,98.5,Low-level tetraploidy or near-tetraploidy,48,"A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells.",6.1,11.28,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.G12C; MAF 97%,"","","","","","","","","","","","","","","","","","","",p.G245S; MAF 96%,"","","",""
14-00712,leaderboard,1810,Male,Male,White,1,n,65,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Pancreatic adenocarcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,65,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Other,3,"3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Salvage,9,Dead,158,Dead-Disease,FALSE,FALSE,"",0,0,18,12,0.9,32,7.4,35.2,18.5,4.8,44,165,2.9,1.65,"",20.1,6.7,"46,XY,i(17)(q10)[20]",3923,81,"TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metaphase analysis.",40,"CD13, CD33, CD34, CD117, and HLA-DR positive",5.7,161.89,FALSE,FALSE,"",negative,negative,"",p.R693fs*10; MAF 49%,"","","","","","","","","","","",negative,"","",p.S893L; MAF 52%,"","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",p.G12D; MAF 46%,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00739,training,1820,Male,Male,White,1,n,39,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",39,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate",3,Induction|CNS|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,4,Dead,216,Dead-Disease,FALSE,FALSE,"",0,0,"","",0,0,28.3,17.7,3.5,0,19,14,3,0.97,"",31.1,10.7,"46,XY,t(6;11)(q27;q23)[20]",,98.4,MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).,31,"",6.2,21.12,FALSE,FALSE,"",negative,negative,"",negative,"","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","",negative,negative,"","",negative,"","",negative,PTD,"",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00774,training,1843,Male,Male,White,4,n,84,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,84,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Decitabine, Midostaurin",1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,-1,Dead,67,Dead-Disease,FALSE,FALSE,"",0,,85,88,,,,,,,"",,,,M0,,,"46,XY[20]",,,"",,"CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT",,30,FALSE,FALSE,"",positive,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00780,training,1098,Female,Female,White,2,n,31,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,38,1496,Post-Chemotherapy|Post-Transplant|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,4,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),9,"Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide",7,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Dasatinib,Experimental,24,Dead,2661,Dead-Unknown,TRUE,TRUE,13-00294,-480,,7,1,,,,,,,15,21,4.2,,"",31.9,11,"46,XX",,,nuc ish(DXZ1x2)[200],45,"",6.2,2.2,FALSE,FALSE,"",negative,negative,"","","","",S259fs*10; MAF 15%,"","","","","",P281R; MAF 19%,"","","","","","","","","","","","","","",D835E; MAF 13%,"",N297S; MAF 18%,"","",Q44*; MAF 14%,"","","","","","",Y2907*; MAF 7%,"","","","","","","","","","","","","",E76V; MAF 17%,"","","",H1100R; MAF 51%,K700E; MAF 18%,"","","","","","","","","","","","",""
14-00781,training,1847,Male,Male,White,1,n,71,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,MiDAC,Consolidation,5,Dead,162,Dead-Disease,FALSE,FALSE,"",0,0,95,80,0,2,21,4,1,0.8,29,282,3.2,1.61,M5,31.8,10,"47,XY,t(1;11)(p32;q23),+8[cp20]",7759,102.3,c/w karyotype,59,"CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive",6.1,71.19,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","",p.Q1765*; MAF 4%,"","","",negative,"","","","",negative,"","","","","","","","","",negative,negative,"",p.G13D; MAF 27%,"",negative,"","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
14-00787,leaderboard,1848,Male,Male,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,442,Alive,FALSE,FALSE,"",0,0,90,90.5,0,0,8.2,2.2,0.9,0.8,22,43,3.1,1.21,M1,17.3,5.2,"46,XY[20]",1873,96.1,Normal,34,"CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)",6.9,427.46,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",p.N307_V308ins; MAF 50%,"","","","","","",negative,"","","","","","","",negative,negative,"","","","","",negative,negative,"",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
14-00798,leaderboard,1852,Female,Female,White,1,n,36,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,36,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Dead,15,Dead-Other,FALSE,FALSE,"",0,0,74,82,1.7,1.7,6.7,82.3,3.4,0,45,36,2.7,0.68,M4,20.4,7.1,"46,XX,inv(16)(p13.1q22)[20]",,87.6,"CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement. ",12,"",5.8,117.53,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",p.G12D; MAF 9%,"",negative,"","","","",p.G12D; MAF 10%,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
14-00800,training,1854,Male,Male,White,1,n,68,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,69,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,n,y,y,1,Standard Chemotherapy,2,"CPX-351 (Liposomal Cytarabine + Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,4,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,4,Dead,114,Dead-Disease,FALSE,FALSE,"",-30,,"","",,,,,,3.6,26,65,3.1,1.07,"",20.9,7.2,"46,XY[20]",1004,90.1,"",17,"",5.4,53.76,FALSE,FALSE,"",negative,negative,"","","","","","","","","",p.C404Y; MAF 28%,"","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","","","","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"",p.K666N; MAF 36%,"","","","","","","",p.L1047fs*11; MAF 34%,negative,"","",negative,""
14-00831,training,1866,Male,Male,HispNative,2,n,26,FALSE,TRUE,FALSE,PML-RARA,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,26,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,5,Unknown,,"",FALSE,FALSE,"",0,,81,37,3,,33,1,15,,47,44,4.4,0.8,"",18.6,6.3,"46,XY,t(15;17)(q24;q21.1)[10]/46,XY[10]",484,,"nuc ish(PML,RARA)x3(PML con RARAx2)[173/200]",105,"CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-/small subset +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(equivocal/appears partial dim +), CD117(+), CD123(-), HLA-DR(-), MPO(appears partial +), TdT(few +).",6.7,4.95,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
14-00832,leaderboard,1868,Female,Female,White,1,n,65,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,IntermediateOrAdverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,0,Alive,450,Alive,FALSE,FALSE,"",0,0.8,"",30,0,12.5,24.2,28.3,18.4,0,23,29,3,0.78,"",22.4,7.4,"",561,107.2,"",60,"CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive",6.6,31.66,FALSE,FALSE,"",positive,negative,negative,"","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","","","","",negative,""
14-00901,training,1870,Male,Male,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,44,Dead,104,Dead-Unknown,FALSE,FALSE,"",-2,0,"","",0,0,45.5,0.8,0,0.3,14,18,2.4,0.73,"",21.3,6.9,"46,XY,t(1;4)(q21;p14)[20]",178,103.4,Normal,57,"",7,13.68,FALSE,FALSE,"",negative,negative,"","","","",p.S571*; MAF 90%,"","","","","","","","",negative,"","","","","","","","","","","",negative,"","",negative,negative,"","",negative,"","",negative,PTD,"",negative,"",negative,"","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","",p.C181F; MAF 88%
15-00043,training,1924,Female,Female,White,5,n,43,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,44,0,Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,12,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,420,Alive,FALSE,FALSE,"",-46,,"","",,,,,,,"",,,,"",,,"46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]",,,Positive for an EVI1 rearrangement,,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00045,training,1925,Female,Female,White,2,n,30,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,30,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,40,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,-1,Alive,854,Alive,FALSE,FALSE,"",0,0,36,22,0,,12,44,5,,61,44,4.2,0.59,"",31.8,11,"46,XX,inv(16)(p13q22)[20]",441,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5’CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200]",33,"CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO",7,55,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00051,leaderboard,1929,Female,Female,White,1,n,66,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,66,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Matched Unrelated Donor,2,Alive,534,Alive,FALSE,FALSE,"",0,0,95,90.2,0,2.5,4.9,0.8,1.6,0.6,19,23,3,0.5,"",18.9,6.1,"",501,100.5,Normal,10,"CD13, CD33, dim CD71, CD117, CD123, and MPO",6.4,66.67,FALSE,FALSE,"",negative,positive,negative,"","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,p.R140Q; MAF 46%,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
15-00057,leaderboard,1933,Male,Male,White,5,n,76,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,76,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,AG-221|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Experimental,"","",,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,680,Dead-Disease,TRUE,TRUE,15-00056,0,,70,55,,,,,,,"",,,,"",,,"46,XY[20]",,,Normal,46,"positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers",,4.5,TRUE,TRUE,15-00056,negative,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","",negative,C.G419A (p.R140Q),"","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00075,training,1964,Male,Male,White,5,n,80,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,80,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Targeted Therapy - Other,1,AG-221,1,Experimental,"","",,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,34,Dead-Disease,FALSE,FALSE,"",1,,90,48,,,,,,,"",,,,"",,,"46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2]",,,Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7,65,"positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT",,6.6,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",C.G395A; p.R132H; MAF unknown,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00084,leaderboard,1953,Female,Female,White,1,n,82,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,82,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,"","",,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,122,Dead,35,Dead-Disease,FALSE,FALSE,"",-21,7.6,"","",4.2,8.5,28,6.8,12.7,0.1,24,22,3.1,0.96,"",31.5,11,"43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]",1304,86.8,"",21,"",7.3,17.63,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00123,training,1969,Male,Male,White,2,n,42,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,42,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1,Alive,832,Alive,FALSE,FALSE,"",0,,81,85,,,4,7,4,,89,50,3,0.94,"",27.8,9.5,"",945,95.5,"",39,"partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT",5.7,48.03,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00147,leaderboard,1981,Female,Female,HispNative,1,n,28,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,30,2,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,5,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) ",Salvage,5,Dead,843,Dead-Disease,TRUE,FALSE,15-00137,-27,0,"","",0,0,4.1,0,2.1,32.3,54,37,3.7,0.3,NOS,27.3,9.2,"46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]",,91.3,"",8,"",6.3,20.18,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00171,leaderboard,2002,Male,Male,White,5,n,80,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,80,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),3,"Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC",3,Consolidation|Salvage|Experimental,"","",,Targeted Therapy - Kinase Inhibitor(s),Decitabine,Salvage,-1,Dead,309,Dead-Disease,FALSE,FALSE,"",1,,80,86,,,,,,,"",,,,"",,,"46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]",,,Positive for deletion of 20q12 in 11.5% of 200 cells,4,"positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5",,,FALSE,FALSE,"",negative,negative,"",p.718_724del; MAF 50.3%,"","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","","","","","","","","","","","","","","","","","",p.S114X; MAF 44.8%,"","","","",p.P95H; MAF 45.1%,"","","","","",negative,"","","",""
15-00175,training,1999,Male,Male,HispNative,1,n,50,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,50,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Salvage|Induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,4,Dead,99,Dead-Disease,FALSE,FALSE,"",0,0,76,93,0,0,6.1,1.7,1.8,0,7,10,2.2,0.44,"",18.8,6.3,"43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]",,85.8,deleted 5q and three short arm signals;  monosomy 7 and the metaphase karyotype;  no evidence for MLL deletion or rearrangement,14,"",5.9,50.74,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","","","","",negative,negative,"","",negative,"","","","","",negative,"",negative,"","","","",p.Q61K; MAF 37%,"","","","","","","","","","","","","","","","","","","",p.R273H; MAF 44%,"","",negative,""
15-00237,training,2028,Female,Female,White,1,n,29,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",IntermediateOrAdverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",29,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide|Transplant",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24,Bone Marrow Transplant,Transplant,Allogeneic - Matched Unrelated Donor,-1,Alive,476,Alive,FALSE,FALSE,"",0,0,95,78,0.9,0,11.7,0,13.5,1.8,20,25,3,0.54,"",23,7.9,"46,XX[20]",1119,95.8,Normal,12,"dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.",6.1,68.79,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",PTD,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00248,leaderboard,2033,Male,Male,HispNative,2,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Unknown,,"",FALSE,FALSE,"",0,0,64,47.4,1.7,,23.3,27.6,0,,29,26,3.7,1.01,"",32.9,10.3,"46,XY[20]",578,99.7,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",20,"CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(-).",7.2,20.8,FALSE,FALSE,"",negative,negative,"",G967DEL; MAF 45%,"","","","","","","","","","","",A111FS*56; MAF 48%,"","","","","","","","","","","","","",A318V; MAf 37%,negative,negative,"","","","","","","","","","","","","","","",G13V; MAF 37%,"","","","","","","","","","","","","","","","","","","","","","","",""
15-00261,training,2052,Female,Female,White,1,n,43,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,43,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Cytarabine,Supportive/Palliative Care,125,Dead,245,Dead-Disease,FALSE,FALSE,"",0,0,"","",0,0,31.9,12.4,2.6,0.1,26,16,3,0.77,M4,22.1,7.5,"46,XY[20]",297,95.7,Normal,59,"",6.5,22.95,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","","","","","","","","","","","",negative,"","","","","","",negative,"","","","","","","","",p.K110Q; MAF 38%,"","","","","","","",p.E261fs*2; MAF 52%,"","",negative,"","","",""
15-00269,training,2053,Male,Male,White,2,n,59,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,107,Dead,430,Dead-Unknown,FALSE,FALSE,"",-1,0,35,27.4,0,,36.8,6.6,29.2,,13,25,2.9,1.4,"",23.6,7.6,"46,XY[20]",383,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",35,"",6,3.6,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",Y181*; MAF 15%,"","","","","","","","","","","","","","","",R140Q; MAF 35%,"","","","","","","","","","","","","","","","","","","",splice site 1164-1G>A; MAF 48%,"","","","","","","","","",P95R; MAF 37%,"","","","","","","","","",""
15-00275,training,1992,Female,Female,White,5,n,53,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Ovarian cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,53,33,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,29,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Re-induction,17,Dead,72,Dead-Disease,TRUE,FALSE,15-00157,-33,,"","",,,,,,,"",,,,"",,,"53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]",,,Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells),,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00276,leaderboard,2059,Male,Male,White,1,n,60,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,3,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)",3,Salvage|Induction|Re-induction,Complete Response,Other,167,Standard Chemotherapy,Azacitidine,Salvage,6,Dead,870,Dead-Unknown,FALSE,FALSE,"",0,0,90,39.6,1,4,47,10,1,0.1,30,26,2.4,1.17,M4,14,4.6,"46,XY[20]",612,104.5,Normal,80,"dim CD4, dim CD7, dim CD11b,      CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT",5.8,70.84,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","",p.V491L; MAF 51%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.K666Q; MAF 47%,"","","","","","","","","","","",p.Y395fs*51; MAF 49%,""
15-00279,training,2087,Female,Female,White,3,n,48,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,48,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16",4,Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"TBI, VP-16",Allogeneic - Matched Unrelated Donor,-1,Alive,435,Alive,TRUE,FALSE,15-00278;15-00322,0,,86,77,,,,,,,"",,,,M5b,,,"46,XX",,,"",,"Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia.",,81,TRUE,FALSE,15-00278;15-00322,positive,positive,"","","","","","","","","","","","","",negative,"","","","","","",p.Arg882Cys; MAF 47.1%,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
15-00287,training,2073,Male,Male,White,1,n,85,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,85,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,"","",,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,105,Dead,167,Dead-Disease,FALSE,FALSE,"",2,0,"","",2.5,0,14.6,2.4,0,0.5,14,15,3.5,0.98,"",33.2,10.7,"46,XY[20]",289,89.5,Normal,8,"",7.4,25.63,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",p.K313_V314insK; MAF 50%,"","","","","","",negative,"","","","",negative,"","","","","","","","","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","",p.I1025L; MAF 50%,negative,"","","",""
15-00296,training,2079,Female,Female,White,1,n,16,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,16,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",1,Induction,Complete Response,Standard Chemotherapy,10,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Induction,10,Alive,318,Alive,FALSE,FALSE,"",0,0,93,0,0,0,33,67,0,0,"",,,0.72,M5,18.2,6.1,"46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]",934,100,"MLL:   14% of cells had a 1 red / 1 green / 1 fused split pattern consistent with the t(9;11) seen on metaphase analysis.  An addition 65% of cells had two red / 1 green / 1 fused signal pattern, consistent with the clone with the +der(9).",39,"CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive",,24.72,FALSE,FALSE,"",negative,negative,"","","","","","",negative,"","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",p.G13D; MAF 6%,"",negative,"","","","",p.Q61H; MAF 19%,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
15-00300,training,2067,Male,Male,White,5,n,76,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,76,1,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Unknown,,"",FALSE,FALSE,"",0,,20,"",,,,,,,"",,,,"",,,"41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2]",,,"Loss of chromosome 5q31 sequences (73.5%)                Loss of chromosome 7 sequences (monosomy 7) (61.5%)                Gain of 21q22 (AML1) sequences (11.5%)                Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences",91,"",,5.6,FALSE,FALSE,"",negative,negative,"",p.E1102D; MAF 31.1%,"","","","","","","","","","","",negative,"","","","","","",p.F543C; MAF 35.7%,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","",""
15-00302,training,2068,Female,Female,White,3,n,65,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,UNKNOWN,Standard Chemotherapy,-1,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1,Dead,21,Dead-Other,FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"",,,"",,"Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia",,,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,p.Ile3572Ser (NM_001197104.1); MAF 44.1%,"",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","",p.His724fs; MAF 43.5%,negative,"","","",""
15-00338,training,2094,Female,Female,White,2,n,42,FALSE,TRUE,FALSE,PML-RARA,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,42,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Other|Intrathecal,3,"ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate",3,Induction|Experimental|Maintenance,Unknown,Intrathecal,22,Standard Chemotherapy,"ATRA, 6-MP, Methotrexate",Maintenance,-1,Alive,155,Alive,FALSE,FALSE,"",0,0,92,83.0,0,,11,4,0,,35,35,3.9,0.66,"",22.2,7.6,"46,XX,t(15;17)(q24;q21.1)[1]",475,88.4,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",35,"CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-).",5.8,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00371,leaderboard,2113,Male,Male,White,2,n,74,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,75,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,48,Dead,324,Dead-Unknown,FALSE,FALSE,"",0,0,32.0,5.0,0,,69,8,18,,23,22,4.3,1.21,"",32.9,11.1,"46,XY[18]",199,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",178,"CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(partial +)",7.1,2.3,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00377,training,2116,Female,Female,White,1,n,10,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,10,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,33,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Re-induction,-1,Alive,569,Alive,FALSE,FALSE,"",0,0,80,75,1.7,6.1,17.4,7.8,11.3,0.7,24,22,3.7,0.51,"",30.3,9.1,"46,XX[20]",688,83.7,Normal,74,"variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive",7.3,39.69,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",p.G96fs*12; MAF ~50%,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,PTD (low level mutation),"",negative,"","","","","","",p.G12D; MAF 5%,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
15-00383,training,2127,Male,Male,Black,2,n,63,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Ruxolitinib|Hydroxyurea,1,Supportive/Palliative Care,"","",,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,103,Dead,8,Dead-Disease,FALSE,FALSE,"",0,1,9,15.4,2.9,,20.2,16.3,42.3,,"",,,0.6,"",22.7,7,"46,XY[20]",1086,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",126,"CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).",,73.4,FALSE,FALSE,"",positive,positive,"",Foundation; W898*; MAF 47%,"","","","","","","","","","","","","","","","","","","","","","","",negative,"","",negative,negative,"","","","","","","","",Foundation; A59T mutation; MAF 47%,"","","","","","","","","","","","","","","","","","","","","","","",Foundation; W617*; MAF 49%,"","","","","","",""
15-00417,training,2135,Male,Male,White,2,n,44,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",n,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,44,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Unknown,,"",FALSE,FALSE,"",0,0,62,19,1,,18,35,25,,24,90,1.8,0.73,"",22.4,7.2,"47,XY,+21[19]/46,XY[1]",,,"nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",18,"CD2(-­), CD7(dim + to -­), CD11b(-­), CD13(+), CD14(-­), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-­), CD38(variably +), CD45(+), CD56(-­), CD64(partial +), CD117(+), HLA-­DR(variably +)",7.1,8,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00464,training,2147,Male,Male,White,2,n,71,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,"","",,Supportive/Palliative Care,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,288,Dead-Unknown,FALSE,FALSE,"",-3,0.9,"","",2.8,,,,,,28,27,4.2,1.18,"",29.3,9.8,"46,XY,inv(4)(p14p16.1)[3]/46,XY[16]",194,,"nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]",73,"",7.1,,FALSE,FALSE,"",negative,negative,"","","","",Foundation; Q1337*; MAF 56%,"","","","","","","","","","","","","",Foundation; R49H; MAF 19%,"","","","","","",negative,"","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","Foundation; loss, splice site 477_508+22>GGG; MAF 50%","","","","",Foundation; R94_S101del;MAF 39%,"","","","",Foundation; splice site 3409+2T>G; MAF 51%,"","","","",""
15-00470,training,2144,Male,Male,HispNative,1,n,32,FALSE,TRUE,FALSE,PML-RARA,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,32,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,1,"ATRA, Arsenic Trioxide",2,Consolidation|Experimental,"","",,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,232,Alive,292,Alive,FALSE,FALSE,"",-2,0,"","",0,19.6,56.3,0.9,3.6,0.1,31,20,3,0.84,"",19.1,6.3,"46,XY,t(15;17)(q22;q21)[20]",,96.5,70% PML/RARA,49,"",6.9,7.19,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","p.E484G, MAF 3%","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","",p.F451C; MAF 51%,""
15-00471,leaderboard,2142,Male,Male,White,3,y,69,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,69,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,"","",,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,250,Dead-Disease,FALSE,FALSE,"",0,,60,"",,,,,,,"",,,,"",,,"",,,"",,"weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61.",,33,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",c.117delC; MAF 27.2%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",c.3454G>T; MAF 40.9%,"","","",c.1137_1138insA; MAF 43.7%,""
15-00482,leaderboard,1532,Female,Female,White,1,n,46,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,424,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Azacitidine,Consolidation,339,Alive,788,Alive,FALSE,FALSE,"",0,0,70,64.6,3.5,0.9,17.7,0,13.3,0,184,77,2.8,0.72,"",37,12.6,"46,XX[20]",,94.4,Normal,138,"CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive",5.7,16.95,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","","","","","",p.R882C; MAF 39%,"","","","","","","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","",p.E76Q; MAF 41%,"","",negative,"","","","","","","","","","",negative,"","",negative,""
15-00534,training,2195,Male,Male,White,5,n,87,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,87,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,AG-120|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Experimental,"","",,Targeted Therapy - Other,AG-120,Experimental,-1,Dead,249,Dead-Disease,FALSE,FALSE,"",1,,60,39,,,,2,,,"",,,,"",,,"47,XY,+21[3]/46,XY[9]",,,9.5% gain 21q22,43,"A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR",,139.9,FALSE,FALSE,"",negative,negative,"",p.G642fs; MAF 31.6%,"","","","","","","","","","","",p.A66fs; MAF 37.3%,"","","","","","","","","","","","","","",p.R132C; MAF 48.7%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.N107D; MAF 97.6%,"","","",""
15-00539,training,2196,Female,Female,White,2,n,72,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,4,"Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine",2,Hypomethylating/Low Dose Cytarabine|Maintenance,"","",,Other,"Clofarabine, Cytarabine",Hypomethylating/Low Dose Cytarabine,-1,Dead,465,Dead-Disease,FALSE,FALSE,"",-79,0,"",25,0,,2,54,18,,41,34,3.6,0.58,"",27.5,8.8,"46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]",,,"nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]",,"",6.2,58.2,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",PB,"",PB,"","","","","","","","","","","","",""
15-00556,training,2202,Male,Male,White,1,n,10,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,IntermediateOrAdverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,10,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Intrathecal|Other,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|MiDAC",2,Induction|Re-induction,Refractory,Intrathecal,10,Standard Chemotherapy,MiDAC,Re-induction,31,Alive,75,Alive,FALSE,FALSE,"",1,0,75,86,0,0,7.5,1.8,4.7,0.1,13,23,3.6,0.47,"",21.6,6.9,"46,XY[20]",970,96,"",42,"variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive",7.8,133.63,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","",p.R142fs*19; MAF 52%,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
15-00559,training,2205,Female,Female,HispNative,5,n,42,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,42,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,3,"7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",3,Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,448,Dead-Unknown,TRUE,FALSE,15-00560,0,,50,51,,,,,,,"",,,,"",,,"46,XX[20]",,,Normal,256,"positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO",,10.7,TRUE,FALSE,15-00560,negative,negative,"",p.G652S; MAF 41.3%,"","","","","","","","","","","",negative,"","","","","","",p.S307fs; MAF 45.6%,"","","","",negative,"","",c.C315T; p.G105G; MAF 46.6%,p.R140Q; MAF 43.8%,"","",negative,"","",negative,"","","","",negative,"","","","","","","","","","","","","","","","","","",p.P95H; MAF 42.2%,"","","","","","","","","",""
15-00563,training,2204,Female,Female,White,1,n,2,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,2,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide",3,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,136,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,428,Alive,FALSE,FALSE,"",0,0,80,52.2,0,1.8,46,0,0,0.2,22,53,,0.24,M1,22,6.9,"46,XX,t(6;11)(q27;q23)[19]/46,XX[1]",,92.8,"",40,"CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive",,57.08,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00578,training,2214,Female,Female,White,1,n,62,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Other,4,"3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,7,Bone Marrow Transplant,"Fludarabine, Melphalan, TBI, ATG",Allogeneic - Child,-1,Alive,27,Alive,FALSE,FALSE,"",0,0,95,67.25,0,0,9.5,23.3,0,0.1,54,57,3.3,0.78,M5,27.4,9.1,"46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]",861,93.2,"MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia",26,"CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR",6.8,87.72,FALSE,FALSE,"",negative,negative,"",p.R693*; MAF 19%,"","",p.S209L (possibly a benign germline polymorphism); MAF 48%,"","","","","","","","",negative,"","","","","","",negative,"","","","",p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%;negative,"","",negative,negative,"","",negative,"","",negative,negative,"",negative,"","","","","","",p.G12S; MAF 19%,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
15-00593,training,2225,Female,Female,White,3,n,71,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Follicular lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,71,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone",4,Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,-1,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,280,Dead-Disease,FALSE,FALSE,"",-1,,82,66,,,,,,,"",,,,"",,,"46,XX,del(7)(q22q36)[20]",,,"ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present",,"CD7, CD13, weak CD33, CD34, CD117, and HLA-DR",,133.7,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",c.1138delinsAA; MAF 31.2%,""
15-00608,leaderboard,2232,Female,Female,White,5,n,61,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,464,Alive,TRUE,FALSE,15-00606,1,,40,28,,,,,,,"",,,,"",,,"46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19]",,,"65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)",26,"positive CD13, CD34, dim CD45, CD117 and HLA-DR",,4.8,TRUE,FALSE,15-00606,negative,negative,"","","","",p.1189_1192del; MAF 33.1%,"","","","","","","","",negative,"","","","","","","","","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","","","",negative,"","","","",p.G12D; MAF 10%,"","","","","","","","","","","","","",p.P95H; MAF 34.4%,"","","","","","","","","",""
15-00610,training,2233,Female,Female,White,5,n,42,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,42,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI ",3,Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,505,Alive,FALSE,FALSE,"",0,,35,2,,,,,,,"",,,,"",,,"46,XX[20]",,,Normal,35,"The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (including some cells with bright CD64), CD11b, an",,49.7,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","","","",negative,"","","","","","","","","","","","","",p.L29S; MAF 52.7%,"","","","","","","","","","","","","","",""
15-00614,training,2234,Male,Male,White,1,n,51,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,51,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,HiDAC|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI,4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,Bu/Cy/TBI,Allogeneic - Mismatched Unrelated Donor,-1,Alive,296,Alive,FALSE,FALSE,"",0,0,"","",0,0,85.8,1.9,8.5,0,25,25,3,0.93,M0,25.1,8.2,"60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]",634,81.8,"EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second clone.",77,"",6.5,0.5,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",p.G13D; MAF ~40%,"","","","","","","","","","","","","","","","","","","",Splice site (5' splice site mutation in intron 4); MAF 44%,"","","",""
15-00615,leaderboard,2235,Female,Female,Asian,3,n,24,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,24,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,6,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",5,Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Dead,633,Dead-Disease,FALSE,FALSE,"",-3,,"","",,,,,,,"",,,,"",,,"46,XX[20]",,,Normal,,"",,,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","",p.Gln41fs; MAF 4%,"","","","","","","","","","","","","","","","","","","",p.Gln865Glu; MAF 48.9%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00616,training,2236,Female,Female,White,1,n,68,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Dead,314,Dead-Disease,FALSE,FALSE,"",-14,2.6,"",49,5.1,6.8,36.8,0.9,14.5,0.2,18,16,2.8,0.67,"",21.9,7.5,"43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1]",821,88.7,"",8,"CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive",7.2,11.01,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.I254N; MAF 40%,"","","",""
15-00633,training,2241,Female,Female,White,3,n,52,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,52,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG, Methotrexate",Allogeneic - Matched Unrelated Donor,-1,Alive,544,Alive,FALSE,FALSE,"",-3,,"","",,,,,,,"",,,,"",,,"46,XX,t(9;11)(p22;q23)[5]",,,11q23 (MLL): rearrangement present,,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Gly13Asp; MAF 38.9%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00650,training,2251,Male,Male,White,1,n,85,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,85,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Induction,Refractory,Standard Chemotherapy,232,Standard Chemotherapy,Azacitidine,Induction,232,Dead,80,Dead-Unknown,FALSE,FALSE,"",0,0,36,23.7,0,8.7,20.2,27.2,20.2,1.6,24,23,3.4,0.88,M4,31.5,9.6,"46,XY,del(12)(p11.2p13)[20]",200,95.7,"ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis. ",46,"CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58.",7,40.53,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Q61R; MAF 30%,"","","","","","","","","","","","","","","","","","","","","",p.S34F ; MAF 50%,"",""
15-00653,training,2254,Female,Female,White,2,n,52,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",52,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1,Dead,633,Dead-Disease,FALSE,FALSE,"",-1,0,83,48.6,0,,9.4,0.9,40.2,,21,47,3.3,0.55,M1,25.3,8.3,"46,XX[20]",,,"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",48,"CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(-), MPO(+).",6.6,22.1,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",Foundation; A680V; MAF 6%,"","",negative,negative,"","","","",Foundation; P738fs*2;MAF 31%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",Foundation; Q742*; MAF 45%,"","","","",""
15-00670,training,2265,Male,Male,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",IntermediateOrAdverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea",4,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,276,Alive,FALSE,FALSE,"",-1,0,92,98,0,0.8,2.6,0,0,0.1,35,23,3.2,0.86,"",19.9,6.8,"46,XY[7]",330,106.4,Normal,49,"dim CD33, CD34, CD38, dim CD45, CD117, and MPO",8,84.96,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","",negative,"","","","","","",p.R882H; MAF ~50%,"","","","",negative,"","",p.R132S; MAF ~50%,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","",p.P95L; MAF ~40%,"","","","","",negative,"","","",""
15-00680,training,2272,Male,Male,White,1,n,68,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,23,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Matched Unrelated Donor,-1,Alive,447,Alive,FALSE,FALSE,"",0,0.9,86,74.8,0,0,2.6,20.8,0.9,0.2,20,28,2.9,1.49,M5,33,10.8,"46,XY[20]",1211,95.9,Normal,83,"Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive",7.2,134.36,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Q156H; MAF 45%,"","","","","","","","","","","","","","","","","","","","","","","","","",p.K666Q; MAF 50%,"","","","","","","","","","","","",""
15-00688,training,2276,Female,Female,White,1,n,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Unknown,Standard Chemotherapy,9,Standard Chemotherapy,Decitabine,Induction,9,Dead,25,Dead-Other,FALSE,FALSE,"",0,1.8,41,2.6,0.9,0,79.6,0.9,14.2,0,21,19,2.7,0.98,"",27.7,9.4,"45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]",404,88.5,"EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo",6,"CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive.",7.6,1.61,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",p.R248Q; MAF 56%,"",p.Q157P; MAF 41%,"",""
15-00692,leaderboard,2277,Female,Female,White,2,n,72,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,73,0,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Azacitidine,Hypomethylating/Low Dose Cytarabine,112,Dead,565,Dead-Disease,TRUE,FALSE,15-00690,0,0,81,43,0,,51,3,2,,11,16,4.5,0.99,M0,28.2,9.6,"46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",10,"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD123(-/few +), MPO(+), TdT(-/few dim +)",6.9,35,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",Foundation; M1fs*60; MAF 34%,"","","","","","","","","","","",negative,"","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",Foundation; splice site 560-2insA; MAF 44%,"","","",""
15-00693,training,2279,Female,Female,White,1,n,66,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",66,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4,"Bortezomib|3+7 (Cytarabine, Daunorubicin)|MiDAC|Fludarabine, Cytarabine",4,Allogeneic - Sibling|Consolidation|Induction|Experimental,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Cytarabine",Allogeneic - Sibling,-1,Alive,838,Alive,FALSE,FALSE,"",0,0,60,"",0,0.9,29.8,54.4,1.8,0.5,23,19,2.5,0.84,"",24.2,7.7,"47,XX,+6[6]/46,XX[19]",453,104.8,"IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH rearrangement and the 14;16 translocation,above",92,"dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.",7.4,14.94,FALSE,FALSE,"",positive,negative,"","","","","p.G1659E MAF ~10%,","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Q61R MAF ~5%,"","","","","","","","","p.P240fs*22; MAF 37%, RUNX1: splice site [at invariant AG (G>A) splice acceptor site at end of Intron 6];  MAF 36% ","","","","","","","","","","","","","","",""
15-00701,training,2280,Female,Female,White,1,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,50,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,6,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Other,Hydroxyurea,Hypomethylating/Low Dose Cytarabine,365,Dead,302,Dead-Unknown,FALSE,FALSE,"",-111,0,"","",0,2.6,8.8,17.6,2.6,0,"",,,,M0,19.8,6.4,"48,XX,+11,+13[19]",,93.4,"",31,"",,206.64,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00702,training,2281,Female,Female,White,1,n,35,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,35,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,10,Standard Chemotherapy,HiDAC,Consolidation,112,Alive,188,Alive,FALSE,FALSE,"",0,1.7,42,29.6,0.9,0,40,18.3,7.8,0.2,54,23,3.5,0.6,"",20.3,6.8,"46,XX,inv(16)(p13.3q22)[21]",319,102.5,"CBFB:  83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype.",63,"Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive.",6.7,12.78,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","","","","","",negative,"","",negative,"","",negative,"","","","","","",p.Q61P; MAF 15%,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
15-00717,training,2295,Male,Male,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Alive,123,Alive,FALSE,FALSE,"",0,0.4,68,0,0.1,3,17,62.6,16.9,0.1,29,17,3.7,1.51,M5,27.7,8.9,"46,XY[20]",296,104.9,Normal,74,"dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive",8,16.84,FALSE,FALSE,"",negative,positive,"",negative,"","","","","","","","","","","","","","","","","","",p.S714C; MAF 35%,"","","","",negative,"","",negative,negative,"","",negative,"","","","","",negative,"",negative,"","","","",p.G13V; MAF 6%,"","","","","",p.A72V; MAF 10%,"","","","","","","","","","","","",p.Q876*; MAF 6%,negative,"","","",""
15-00734,leaderboard,2293,Female,Female,White,1,n,53,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,53,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,SWOG S1203 (7+3 +/- Vorinostat),1,Induction,Complete Response,Standard Chemotherapy,153,Standard Chemotherapy,SWOG S1203 (7+3 +/- Vorinostat),Induction,153,Alive,202,Alive,FALSE,FALSE,"",0,0,93,80,0,1.7,19.3,20.2,13.2,0.6,47,37,3.1,0.79,M5,26.8,8.8,"46,XX[20]",977,92.1,Normal,36,"Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64",6,42.34,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","",p.D835Y; MAF: 40%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00742,leaderboard,2300,Female,Female,White,1,n,34,FALSE,FALSE,FALSE,PML-RARA,FALSE,FALSE,y,Pituitary macroadenoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,34,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,n,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",1,Induction,Unknown,Standard Chemotherapy,-1,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Induction,-1,Alive,0,Alive,FALSE,FALSE,"",1,0,96,47,0,4,60,14,22,0,21,15,4,0.58,M3,30.1,10.7,"46,XX,t(15;17)(q22;q21)[8]/46,idem,add(6)(p23),der(6)add(6)(p21)add(6)(q13),add(9)(p22),add(11)(q21),add(14)(q24)[12]",191,95.9,21/200 (10.5%) interphase cells  scored had the 1 red/ 1 green/ 2 yellow fusion signal pattern consistent  with PML/RARA fusion.,32,"CD13, CD33, CD38, CD58, CD64, CD117, CD123, and  MPO-positive",7,0.5,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
15-00755,training,2304,Male,Male,White,3,n,59,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,-1,Dead,256,Dead-Treatment,FALSE,FALSE,"",-1,,93.2,47.5,,,,,,,"",,,,"",,,"46,XY,t(3;4)(p21;q25)[3]/46,XY[17]",,,"",,"CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64",,42.91,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","",c.2251T>C; MAF 36.9% (33.1% on 3/13/15),"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00756,leaderboard,2305,Male,Male,White,1,n,36,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,36,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea",2,Consolidation|Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,103,Alive,213,Alive,FALSE,FALSE,"",0,0,25,38,0,3.4,29.1,2.6,23.9,0,32,39,2.3,0.7,"",21,7.5,"45,X,-Y,t(8;2;21)(q22;p21;q22)[20]",,104.5,RUNX1T1/RUNX1: (92%),29,"CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO",6.7,24.98,FALSE,FALSE,"",negative,negative,"","","","","","","","","",p.E369_Y371delinsH; MAF 31%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00763,training,2307,Male,Male,White,3,n,23,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,23,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)",2,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)",Allogeneic - Matched Unrelated Donor,-1,Alive,466,Alive,FALSE,FALSE,"",-4,,"","",,,,,,,"",,,,"",,,"46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]",,,62% t(8;21) (RUNX1T1;RUNX1) translocation present,,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","",c.6275_6276delTT; MAF unlisted,"","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00766,training,2310,Male,Male,White,5,n,71,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,71,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,Lenalidomide|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,"","",,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Dead,11,Dead-Other,FALSE,FALSE,"",0,,60,14,,,,7,,,"",,,,"",,,"45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q22)x2,-6,+8,+8,add(8)(p23)x2,",,,"FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.",17,"Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry.",,21.6,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","",p.G355D; MAF 33.8%,p.P19H; MAF 8.9%,"","","",""
15-00767,training,2311,Male,Male,White,2,n,78,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,78,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Hypomethylating/Low Dose Cytarabine,"","",,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Dead,347,Dead-Disease,FALSE,FALSE,"",0,0.2,25,4,1,,25,10,60,,22,21,4.5,0.82,"",47.3,15.3,"46,XY[20]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",15,"CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+)",7.5,5.79,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00777,training,2314,Male,Male,White,1,n,68,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Leukapheresis,y,y,y,y,y,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,7,Dead,122,Dead-Unknown,FALSE,FALSE,"",-1,0,"",83,0,0.8,8.1,9.8,1.6,0.7,29,137,3.3,2.67,M5,35.5,11.4,"46,XY[20]",3615,92.4,normal,104,"CD11b, partial CD13, partial CD14, CD33, partial CD56, CD58, CD64, subset HLA-DR (20%) and partial MPO positive",6.4,140.18,FALSE,FALSE,"",negative,negative,"",p.G645fs*12; MAF 52%,"","","","","","","","","","","","","","","","","","","","","","","","","","",p.R132L; MAF 47%,"","","","","","","",Partial tandem duplication,"",p.G12A; MAF 36%,"","","","","","","","","","","","","","","","","","","","",p.P95H; MAF 49%,"","","","","","","","","",""
15-00786,leaderboard,2322,Male,Male,White,1,y,40,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,40,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,5,Alive,164,Alive,FALSE,FALSE,"",0,0,80,27.8,0,0,62.6,4.4,5.2,0,26,22,3.9,0.78,"",37.6,13.2,"46,XY[20]",,91.7,normal,66,"dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+.",7.4,2.68,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",p.S28fs*81; MAF 28%,"","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.R378W; VAF 100%
15-00807,training,2333,Female,Female,HispNative,1,n,14,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,14,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Busulfan, Cyclophosphamide",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,189,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,252,Alive,FALSE,FALSE,"",-3,,"","",,,,,,,"",,,,"",,,"46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]",,,"All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).",,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","",p.G79S; MAF 50%,"","","","","","","","","","",p.D816Y; MAF 45%,"","","","","","","","","",p.G12D; MAF 45%,"","","","","","","","","","","","","","","","","","","","","","","",""
15-00811,leaderboard,2337,Male,Male,White,1,n,53,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54,7,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",4,Induction|Experimental|Re-induction|Maintenance,Unknown,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1,Dead,168,Dead-Disease,TRUE,FALSE,15-00799,-7,0,"","",1.7,0.9,6.1,8.8,43,0.4,38,29,3.4,0.71,"",27,9.1,"46,XY,add(3)(p24)[cp4]/46,XY[14]",321,95.1,normal,170,"",6.7,16.65,FALSE,FALSE,"",positive,positive,"","","","","","","","","",p.I423N; MAF <0.5%,"","","","","","","","","","",p.R882C; MAF 0.9%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Q548*; MAF 0.7%,"","","","",""
15-00813,leaderboard,2339,Female,Female,White,1,n,53,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",53,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,4,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,7,Alive,119,Alive,FALSE,FALSE,"",1,0,45,50,0,19.4,6.4,1.6,11.3,0,73,83,3.3,0.88,"",29.4,9.6,"46,XX[20]",2008,109.3,Normal,33,"partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO",6.8,137.54,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","",p.R882H; MAF 45%,"","","","",p.D835Y; MAF 3%,"","","","","","","","","","",Partial Tandem Duplication,"","","","","","","","",p.G13D; MAF 35%,"","","","","","","","","","","","","","","","","","","","","","","",""
15-00837,training,2350,Male,Male,White,3,n,72,FALSE,FALSE,TRUE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,72,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,Azacitidine|Momelotinib,2,Hypomethylating/Low Dose Cytarabine|Experimental,"","",,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,188,Dead-Disease,FALSE,FALSE,"",-141,,"",58,,,,,,,"",,,,"",,,"46,XY,inv(16)(p13.1q22)[20]",,,"",,"",,8.21,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00855,leaderboard,2360,Male,Male,HispNative,1,n,8,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,8,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,2,"ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine",2,Induction|CNS,Complete Response,Standard Chemotherapy,151,Intrathecal,Cytarabine,CNS,151,Alive,172,Alive,FALSE,FALSE,"",-2,10.8,"","",0,1.8,8.1,13.5,8.1,0,13,25,3.2,0.72,"",26.8,9.3,"47,XY,+21c[20]",,90.5,RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.,40,"",8.2,67.53,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
15-00858,training,2362,Female,Female,White,1,n,76,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,76,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"5+2 (Cytarabine, Idarubicin)|Decitabine",2,Induction|Re-induction,Refractory,Standard Chemotherapy,8,Standard Chemotherapy,"5+2 (Cytarabine, Idarubicin)",Re-induction,4,Dead,26,Dead-Disease,FALSE,FALSE,"",0,0,95,0,0,0.9,16.8,3.5,24.8,1.1,23,22,3.5,1.33,"",31.5,10.3,"46,XX[22]",244,92.6,Normal,29,"dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive",7,27.17,FALSE,FALSE,"",positive,positive,"",p.G966delG; MAF 50%,"","","","","","","","","","","",negative,"","","","","","",p.R736H; MAF 45%,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
15-00870,leaderboard,2364,Male,Male,White,6,n,71,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,Vidaza|Rituximab|Decitabine,2,Consolidation|Maintenance,"","",,Standard Chemotherapy,Decitabine,Maintenance,86,Dead,51,Dead-Disease,FALSE,FALSE,"",0,,20,10,1,,22,48,16,,6,33,3.7,1.57,"",26,8.1,"46,XY[20]",,91.9,"",13,"Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3",7,44.8,FALSE,FALSE,"",negative,negative,"","","","",p.A603pfs*66; MAF55%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.G12V; MAF 49%,"","","","","","","","","","","","","","","",pR320*; MAF 47%,"","","","",p.P95H; MAF 49%,p.Y636*; MAF 96%,"","","","","","","","",""
15-00872,training,2367,Female,Female,White,1,n,65,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Other,4,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea",4,Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,181,Alive,FALSE,FALSE,"",0,0,74,60,1.9,15.1,21.7,50,11.3,0,23,32,2.6,0.78,"",21.6,7.2,"46,XX[20]",905,100.5,Normal,150,"partial variable CD7, subset CD11b (75%), CD13, CD33, partial CD14 (30%), partial CD64 (70%), CD38, CD58, partial CD117 (30%), CD123, HLA-DR, and partial (50%) MPO positive",6.7,84.69,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","",p.K298Q; MAF 25%,"","","","","","",p.R882C; MAF 44%,"","","","","","","","",p.R140Q; MAF 18%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00874,training,1973,Male,Male,White,1,n,70,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,71,281,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Alive,523,Alive,FALSE,FALSE,"",0,0,90,90,0,0,27.8,2.9,8.6,0.4,81,43,3.3,,"",31.9,10.2,"47,XY,+4[2]/46,XY[18]",235,94.7,"Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.",91,"partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117",6.6,73.42,FALSE,FALSE,"",negative,negative,"",p.Q588*; MAF 49%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00883,leaderboard,2416,Female,Female,White,1,n,72,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib",2,Induction|Experimental,Refractory,Standard Chemotherapy,10,Targeted Therapy - Kinase Inhibitor(s),Ponatinib,Experimental,15,Dead,118,Dead-Disease,FALSE,FALSE,"",0,0.9,90,78,0,0,2.7,3.6,17.3,1.4,28,23,2.8,0.56,"",31.7,9.9,"46,XX[20]",261,98.1,Normal,211,"CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO",6.5,24.01,TRUE,FALSE,15-00884,positive,positive,"","","","","","","","","","","","","",p.E163*; MAF 39%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00892,leaderboard,2421,Female,Female,White,3,n,72,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Targeted Therapy - Other,1,SGN-CD33A,1,Experimental,"","",,Targeted Therapy - Other,SGN-CD33A,Experimental,-1,Dead,179,Dead-Disease,FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"",,,Normal,,"",,,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","",c.2645G>A; MAF 45.4%,"","","","",c.2503G>T (D835Y); MAF 15.5%,"","","","","","","","","","","","","","","","","","","","","","","","","",c.178G>C; MAF 8.4%,"","","","","","","","","","","","",c.3955-2A>G; MAF 45.4%,"","","","",""
15-00900,leaderboard,2420,Male,Male,White,1,n,24,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,24,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Decitabine|Busulfan, Cyclophosphamide",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,7,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Mismatched Unrelated Donor,-1,Alive,187,Alive,FALSE,FALSE,"",0,0,"","",1.8,0.9,23.9,23,7.9,0,37,28,3.7,0.95,"",32.3,11.3,"46,XY[20]",243,92.8,Normal,102,"",7.1,21.84,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.G12C; MAF 40%,"","","","","","","","","","","","","","","","","","","","","","","",""
15-00903,training,2423,Male,Female;Male,White,3,n,73,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Lung Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,73,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,"","",,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,7,Dead,36,Dead-Disease,FALSE,FALSE,"",-24,,"",79,,,,,,,"",,,,"",,,"45,X,-Y[20]",,,Normal,,"",,19.64,FALSE,FALSE,"",negative,negative,"",c.1940dup; MAF 37.9%,"","","",c.3496dup: MAF 7.5%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",c.319C>G; MAF 73.9%,"","","","","","","","","",c.3803+1G>A; MAF 39.3%,"","","","",""
15-00909,training,2425,Female,Female,Black,6,n,44,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,47,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Targeted Therapy - Other,1,Radiation,1,Unknown,"","",,Targeted Therapy - Other,Radiation,Unknown,14,Unknown,,"",TRUE,FALSE,15-00910,0,,90,45,0,,28,5,1,,30,41,3.3,0.82,"",29.3,9.6,"46,XX[20]",,89.9,This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells examined.,5,"The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers.",7.3,6.5,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00912,training,2426,Female,Female,White,6,n,76,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,77,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Unknown,1,Azacitidine,1,Unknown,"","",,Unknown,Azacitidine,Unknown,424,Dead,151,Dead-Unknown,FALSE,FALSE,"",0,,86,50,1,,14,5,20,,32,20,2.9,0.62,"",24.3,7.8,"48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]",,84.1,"",27,"POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58.",5.4,14.3,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00936,training,2337,Male,Male,White,1,n,53,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54,63,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",4,Induction|Experimental|Re-induction|Maintenance,Unknown,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1,Dead,168,Dead-Disease,TRUE,FALSE,15-00938;15-00799,2,1.8,"","",3.6,6.2,23.2,18.7,17,1.3,29,41,3.6,1,"",20.9,6.9,"46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]",,96.3,normal,21,"",6.8,20.77,TRUE,FALSE,15-00938,positive,positive,"","","","","","","","","","","","","","","","","","","","",p.R882C; MAF 45%,"","","","",p.D835H; MAF 15%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Q548*; MAF 45%,"","","","",""
15-00939,training,2314,Male,Male,White,1,n,68,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,72,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,7,Dead,122,Dead-Unknown,TRUE,TRUE,15-00777,-39,0.8,"","",0.9,0,9.3,0,0,0.5,12,14,2.5,0.9,"",20.6,6.4,"46,XY[19]",,90.4,normal,60,"",6.3,6.21,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00942,training,2437,Female,Female,Black,6,n,30,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,31,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,n,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,27,Standard Chemotherapy,HiDAC,Consolidation,93,Unknown,,"",TRUE,FALSE,15-00943,0,,27,43,,,12,40,5,,35,62,4.6,1.01,"",26.1,8.5,"46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1]",,90.6,"This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample.",5,"There are increased abnormal cells in the """"monocyte"""" gate that stain positive for CD38, CD11b, CD14, CD64, CD33, with partial MPO, HLADR, CD13 expression.",7.3,5.3,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00961,training,2444,Female,Female,White,1,n,52,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,52,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,8,Standard Chemotherapy,HiDAC,Consolidation,81,Alive,181,Alive,FALSE,FALSE,"",0,0,"","",30,13,9,21,19,0.1,54,50,2.2,0.84,"",18.8,6.5,"",,98.9,"",21,"",6.5,65.58,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.K2181R ; MAF 50%,"","","","","","","","","","","","","","",p.P95H ; MAF 50%,"","","","","","","","","",""
15-00965,training,2447,Female,Female,White,1,n,61,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC",4,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,187,Alive,FALSE,FALSE,"",0,0,"","",0,0,89.9,9.3,0.8,0,43,31,2.4,0.5,"",19.5,6.5,"",313,92.4,normal,32,"",5.8,67.36,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","",p.R2353Q; MAF 51%,"","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Q270*; MAF 90%,"","","","",""
15-00967,training,2416,Female,Female,White,1,n,72,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,40,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib",2,Induction|Experimental,Refractory,Standard Chemotherapy,10,Targeted Therapy - Kinase Inhibitor(s),Ponatinib,Experimental,15,Dead,118,Dead-Disease,TRUE,FALSE,15-00933,-15,0,70,3.56,0,1.8,34.8,3.6,0.9,23.2,13,40,3.2,0.55,"",22.7,7.5,"46,XX[5]",339,89.7,Normal,32,"CD13+, CD33+, CD38+, variable partial CD56+, partial CD64+, CD117+, dimCD123+, and MPO+",6.4,6.04,TRUE,FALSE,15-00933,positive,positive,"","","","","","","","","","","","","",p.E163*; MAF 40%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
15-00975,leaderboard,2452,Female,Female,White,6,n,70,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",70,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Induction,Unknown,Standard Chemotherapy,37,Standard Chemotherapy,Azacitidine,Induction,37,Unknown,,"",FALSE,FALSE,"",0,,90,17,,,20,18,2,,24,26,3.8,0.76,"",25,8.2,"46,XX,del(5)(q22q35)[20]",,87.7,Positive for 5q deletion in 91% of cells.,35,"POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10.",6.2,7.7,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","",PTD,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.S34F; MAF 35%,"",""
15-00976,training,2453,Male,Male,White,1,n,83,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,83,0,Residual Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,"AG-221|Azacitidine, SGN-CD33A",2,Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,434,Dead-Disease,FALSE,FALSE,"",0,0.3,12,3,0,9.4,26.9,24.5,38.9,0,42,47,3.2,1.3,"",21.1,6.8,"46,XY[20]",,87.9,Normal,213,"CD13, CD33, CD34, CD38, dim CD58, CD117, and dim HLA-DR positive",6,3.72,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","",p.M2408V; MAF 48%,"","","","","","","","","","","","",p.R140Q; MAF 47%,"","","","","","","","","","","","","","","",p.G12D; MAF 49%,"","","","","","","","","","","","","","","","","","","","","","","",""
15-00990,training,2459,Female,Female,White,1,n,81,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,81,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Azacitidine,1,Supportive/Palliative Care,"","",,Supportive/Palliative Care,Azacitidine,Supportive/Palliative Care,6,Dead,14,Dead-Disease,FALSE,FALSE,"",0,0,90,70,0,0.8,6.1,72.2,12.2,0.4,62,50,2.9,4.22,M5,22.8,7.3,"46,XX[20]",262,90.8,Normal,29,"CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive",5.8,97.26,FALSE,FALSE,"",negative,positive,"",p.W796fs*22; MAF 48%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","",p.S825fs*1; MAF 49%,"","","","",""
16-00001,training,2460,Female,Female,White,1,n,36,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,36,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|Hydroxyurea",3,Consolidation|Induction|Experimental,Refractory,Standard Chemotherapy,1,Standard Chemotherapy,HiDAC,Consolidation,122,Alive,209,Alive,FALSE,FALSE,"",-2,0,40,60,1.7,0,33.4,5.1,18.8,0.1,38,28,3.2,0.53,"",22.9,7.6,"46,XX,t(16;16)(p13.2;q22)[20]",508,99.6,"CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.",24,"Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive.",7.3,20.44,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.T417_D419delinsY; MAF 33%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00003,training,2461,Male,Male,White,3,n,26,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,27,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,16,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,603,Alive,FALSE,FALSE,"",-7,,"","",,,,,,,"",,,,"",,,"46,XY[15]",,,Normal,,"",,,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Arg140Gln; MAF 45.9%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00004,leaderboard,2462,Female,Female,White,1,n,82,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,82,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Dead,268,Dead-Disease,FALSE,FALSE,"",0,0,50,"",0,1.8,42.8,0,5.4,3.7,13,18,2.8,1.03,"",27.7,9.2,"46,XX",279,91.1,trisomy 8 in 5 of 20 metaphase cells,44,"",7,1.36,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","",p.R882H; MAF 39%,"","","","","",p.R191C; MAF 51%,"","",p.R172K; MAF 36%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00007,training,2464,Male,Male,White,4,n,77,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine, Sorafenib|Decitabine, Midostaurin",2,Induction|Re-induction,Refractory,Standard Chemotherapy,165,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,-1,Alive,217,Alive,TRUE,TRUE,16-00006,0,,41,18,,,,,,,"",,,,"",,,"46,XY[20]",,,"CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)",,"ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56",,2.2,TRUE,TRUE,16-00006,positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00027,leaderboard,2473,Male,Male,AdmixedWhite,2,n,55,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib",4,Consolidation|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Cyclophosphamide,Maintenance,1,Alive,393,Alive,FALSE,FALSE,"",0,0,91,99.2,0,,0.8,0,0,,33,27,3,0.85,"",18.8,6.2,"46,XY[29]",808,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",28,"CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(-), MPO(+)",6.1,181.08,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","",R132H; MAF 47.0%,negative,"","","","","","",Foundation; MLL-PTD Exons 2-8; not GeneTrails,"","","","","","","","","","","","","","","","","","","","","","","","","","","",SPLICE SITE 3500+1G>A; MAF 48.0%,"","","","",""
16-00031,leaderboard,2477,Male,Male,White,6,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",50,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Allogeneic - Sibling|Induction|Re-induction,Unknown,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,97,Alive,576,Alive,TRUE,FALSE,16-00030,0,,75,73,,,6,6,8,,44,20,3.5,1,"",24.8,8,"46,XY[20]",,91.5,Not Available (no FISH done),26,"These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b.",5.8,17.1,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00048,training,2483,Female,Female,Asian,1,n,46,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Anaplastic Astrocytoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,46,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,7,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG",4,Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,1,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,637,Dead-Disease,FALSE,FALSE,"",0,0.9,25,26.7,1.7,4.3,6.1,32.2,48.7,0.2,14,15,3.1,0.64,"",32,9.5,"46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]",440,80.6,Normal,92,"Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a",6.8,42.57,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","",p.I824V; VAF 50%,"","","","","",p.S412R; MAF 60%,"","","","","","","","","","","","","","","","","","",p.G13R; MAF 50%,"","","","","","","","",p.T196I ; MAF 50%,"","","","","","","","","","","","",p.I24T; MAF 5%,"",""
16-00056,training,2490,Female,Female,White,1,n,51,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,51,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,2,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,201,Alive,FALSE,FALSE,"",0,0,95,95,0,0,7.8,0,3.1,0.1,22,12,2.9,0.93,"",20.6,6.6,"46,XX[20]",189,112.6,Normal,57,"Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive",6.5,25.02,FALSE,FALSE,"",negative,positive,"","","","","","","","","",p.R420Q; MAF ~20%,"","","","","","","","","","","","","","","",p.N841K; MAF ~30%,"","","",p.R140Q; MAF ~30%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00067,leaderboard,2496,Female,Female,HispNative,2,n,53,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,53,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI ",4,Consolidation|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Cyclophosphamide,Maintenance,1,Alive,517,Alive,FALSE,FALSE,"",-1,0,20,8,0,,37,20,30,,18,23,3.3,0.86,"",20,6.2,"46,XX[20]",426,105.3,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",38,"CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-).",7,6.63,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,R140Q; MAF 51.0%,"","","","","","",Foundation; MLL-PTD exons 2-10,"","","","","","","","","",V26G; MAF 1.0%,"","","","","","","","","","","","",R94_S101DEL; MAF 40.0%,"","","","","","","","","",""
16-00073,leaderboard,2443,Female,Female,White,1,n,63,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,44,Residual Relapse,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,6,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea",6,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Maintenance|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,29,Dead,348,Dead-Disease,TRUE,FALSE,15-00954,-44,1.5,"",38.5,0,0,55,3.5,1.5,0,25,22,3.8,1.3,"",21.1,7.1,"48,XX,+8,+21[16]/46,XX[4]",,91.3,"RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn",18,"",7.7,19.76,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00075,training,2498,Male,Male,White,4,n,69,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,69,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7,Alive,13,Alive,FALSE,FALSE,"",0,,39,11,,,,,,,"",,,,"",,,"45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]",,,"COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML",,Positive,,1.6,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","",negative,"","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00077,leaderboard,2500,Male,Male,White,2,n,78,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Esophageal Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,80,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",4,Consolidation|Induction|Experimental|Maintenance,Complete Response,Standard Chemotherapy,7,Targeted Therapy - Other,AG-120,Experimental,-1,Dead,605,Dead-Disease,FALSE,FALSE,"",-29,0,"",70,0,,7,3,9,,11,57,2.6,1.28,"",25.6,8.1,"45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]",1897,,"nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",23,"CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +).",4.3,240.43,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00078,leaderboard,2499,Female,Female,White,2,n,67,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,"","",,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Unknown,,"",FALSE,FALSE,"",0,0.8,85,7.7,0,,5.1,42.7,40.2,,27,41,1.9,0.66,"",28.7,9.5,"46,XX[20]",670,102.5,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",42,"CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+).",5.7,56.03,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,negative,"","","","","","","","","","","","","","","",Q61K; MAF 43.0%,"","","","","","","","","","","","","","","","","","","","","","","",""
16-00088,training,2442,Female,Female,AdmixedBlack,6,n,25,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",26,49,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin",3,Consolidation|Induction|Re-induction,Unknown,Standard Chemotherapy,-1,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,67,Dead,324,Dead-Unknown,FALSE,FALSE,"",0,,98,95,,,2,3,,,46,30,4.1,0.54,"",27.2,8.9,"46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]",,90.4,This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.,81,"These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed.",6.9,67.7,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00094,training,2501,Female,Female,White,1,n,37,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",37,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,8,Standard Chemotherapy,Azacitidine,Consolidation,-1,Alive,17,Alive,FALSE,FALSE,"",0,1.7,95,74,2.5,0.8,13.6,14.4,10.2,0.4,23,14,3.1,0.46,"",27.9,9.2,"46,XX[20]",,89.4,Normal,49,"variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR",7,26.57,FALSE,FALSE,"",negative,negative,"",p.A1312V; MAF 50%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.K117N; MAF 48%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.R380fs*69 (1 bp deletion with frameshift); MAF 48%,""
16-00102,training,2508,Male,Male,White,4,n,72,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea,1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,CPX-351 (Liposomal Cytarabine + Daunorubicin),Induction,-1,Alive,95,Alive,FALSE,FALSE,"",0,,97,96,,,,,,,"",,,,M1,,,"46,XY[5]",,,"D5S721, EGR1  del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)   ",,"CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR",,125.9,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","",p.D839G; MAF~45%,"","","",p.R140L; MAF ~50%,"","","","","",negative,"",p.V2338I; MAF ~50%,"","","","","","","","","","","","","","","","","","","","","","p.P95H, MAF~55%","","","","","","","","","",""
16-00109,leaderboard,2511,Male,Male,White,1,n,76,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",n,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,76,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Hydroxyurea,1,Supportive/Palliative Care,"","",,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,7,Dead,8,Dead-Unknown,FALSE,FALSE,"",-1,0,96,93.3,0,0.7,4.7,0,1.3,0.6,23,43,2.3,0.46,"",31,10.4,"46,XY[20]",839,93.9,Normal,17,"CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive",5.1,230.05,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.W564*; MAF 50%,"","","","",""
16-00113,training,2521,Male,Male,White,5,n,85,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,85,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Unknown,,"",TRUE,FALSE,16-00114,0,1.5,2,"",24,,11.5,8,55,,4,8,3.7,1.2,"",48.8,16.1,"46,XY[20]",,,Normal,141,"",6.3,11.4,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","",c.436G>C; p.D146H,"",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","",c.5182G>T; p.E1728X,negative,"","","",""
16-00115,training,2522,Male,Male,White,6,n,74,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",74,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Dead,14,Dead-Disease,FALSE,FALSE,"",0,,19,7,4,,12,2,51,,29,38,3.7,0.86,"",24.2,7.8,"45,XY,-7,del(12)(p11.2p13)[20]",,90.6,Monosomy 7 is detected in 87% of cells.,35,"",6.6,47.5,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00118,training,2443,Female,Female,White,1,n,63,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,58,Residual Relapse,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,6,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea",6,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Maintenance|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,29,Dead,348,Dead-Disease,TRUE,FALSE,15-00954,-58,0,"","",0,0,12.6,0,0,0.2,16,36,3.1,1.57,"",20.9,7,"48,XX,+8,+21[16]/46,XX[4]",887,89.7,"RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn",21,"",7.3,49.93,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00120,leaderboard,2515,Male,Male,White,3,n,36,FALSE,TRUE,FALSE,PML-RARA,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,36,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin",3,Consolidation|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Methotrexate, Mercaptopurine, Tretinoin",Maintenance,-1,Alive,514,Alive,FALSE,FALSE,"",-1,,91.8,95,,,,,,,"",,,,"",,,"46,XY,t(15;17)(q24;q21)[18]/46,XY[2]",,,Normal,,"weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase",,55.42,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00139,training,2530,Female,Female,White,6,n,73,FALSE,FALSE,TRUE,Unknown,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,0,Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Ruxolitinib,1,Induction,Unknown,Standard Chemotherapy,28,Standard Chemotherapy,Ruxolitinib,Induction,28,Dead,560,Dead-Unknown,FALSE,FALSE,"",0,,"","",0.5,,39.2,7.5,52.5,,10,21,4.5,0.87,"",34.1,10.9,"",,92.4,"",6,"",7.6,3.8,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.R140Q; MAF 32%,"","",p.V617F; MAF 30%,"","","","","","","","","","","","","","","","","","","","","","","","","","",p.R94dup; MAF 31%,"","","","","","","","",p.R440Tfs*14; MAF 29%,""
16-00145,training,2533,Male,Male,Asian,2,n,75,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,75,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Vidaza|Decitabine|Fludarabine, Cytarabine",2,Salvage|Supportive/Palliative Care,"","",,Standard Chemotherapy,"Fludarabine, Cytarabine",Salvage,-1,Dead,159,Dead-Disease,FALSE,FALSE,"",0,0,27,2,0,,60.2,8.4,29.4,,12,15,4.8,0.98,"",30.7,9.3,"46,XY,t(1;12)(p32;p13)[3]/46,XY[17]",215,,"nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]",121,"CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +).",7.5,3.09,FALSE,FALSE,"",negative,negative,"",G646fs*12; MAF 37.0%,"","",S1608*; MAF 3.0%,"","","","","","","","","","","","","","","","","","","","",negative,"","",negative,negative,"","","","","","","","",G12R; MAF 5.0%,"","","","","","","","","","","","","","","","","","","","","",Q932fs*6; MAF 91.0%,"",E601fs*10; MAF 38.0%,"",C127fs*92; MAF 6.0%,"","","","",""
16-00157,training,2538,Male,Male,White,1,n,67,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,4,"AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,-1,Alive,528,Alive,FALSE,FALSE,"",0,0,93,94,0,0,1,2.8,1.9,0.1,20,30,2.4,1.23,"",31.2,10.1,"46,XY[20]",,96.3,Normal,30,"partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+.",,125.16,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","","","","","",p.R882H; MAF 46%,"","","","",p.V592D; MAF 43%,"","",p.R132H; MAF 46%,negative,"","","","","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,p.K459E; MAF 50%,"","","","","","","","","",negative,"","",negative,""
16-00217,training,2569,Male,Male,White,1,n,86,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,86,0,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,3,AG-221|Azacitidine|Hydroxyurea,3,Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental,"","",,Standard Chemotherapy,Hydroxyurea,Consolidation,55,Dead,596,Dead-Disease,FALSE,FALSE,"",0,0,23,12.1,0,0.8,8.6,19,59.5,0,16,15,3.4,1.52,"",27.8,9,"47,XY,+8[20]",398,97.5,"(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype. ",299,"dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive",7.6,10,FALSE,FALSE,"",negative,negative,"","","","",p.S1139*; MAF 80%,"","","","","","","","",p.R343fs*79; MAF 40%,"","","","","","",p.G707fs*72; MAF 45%,"","","","","","","","",p.R140Q; MAF 40%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.P95H; MAF 40%,"","","","","","","","","",""
16-00220,training,2571,Male,Male,White,3,n,67,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|IDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,IDAC,Consolidation,-1,Alive,31,Alive,FALSE,FALSE,"",0,,71.5,56,,,,,,,"",,,,"",,,"46,XY[20]",,,Normal,,"CD33, CD38, CD56, CD117, and myeloperoxidase",,16.24,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Leu1780fs; MAF 46.3%,"","","","",p.Arg126*; MAF 97.7%
16-00226,training,2503,Male,Male,White,1,n,79,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79,35,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,4,Azacitidine|Decitabine|Hydroxyurea|V212,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,"","",,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Alive,53,Alive,TRUE,FALSE,16-00092,-35,1.7,"",35,0,0,0.9,64.4,8.7,0.2,9,22,3.1,2.11,"",25.5,7.8,"46,XY[22]",722,95.5,Normal,438,"CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive",5.8,116.52,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00249,training,2581,Male,Male,White,6,n,75,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Vidaza,1,Supportive/Palliative Care,"","",,Standard Chemotherapy,Vidaza,Supportive/Palliative Care,-1,Alive,302,Alive,FALSE,FALSE,"",0,,60,50,,,,2,,,"",,,,"",,,"46,XY[20]",,,"",,"These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers",,25,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00269,leaderboard,2593,Female,Female,White,1,n,44,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,44,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,8,Standard Chemotherapy,HiDAC,Consolidation,99,Alive,170,Alive,TRUE,FALSE,16-00268,0,0,65,11.2,3.5,0,76.7,0,8.6,0,19,11,2.8,0.53,"",23.7,7.8,"",197,100.4,Normal,222,"CD13, CD33, CD117, CD123, dim HLA-DR and MPO",6.1,2.41,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.R132H; MAF 44%,"","","","","","","","","","","","","","","","","","","","","","",p.R265Q; MAF 3%,"","","","","","","","","","","","","","","","","",""
16-00271,leaderboard,2594,Female,Female,White,2,n,22,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,22,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3,"Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib",3,Allogeneic - Sibling|Induction|Experimental,Complete Response,Standard Chemotherapy,39,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,464,Alive,FALSE,FALSE,"",-1,0,63,42,0,,32.7,4.4,26.6,,27,39,3.1,0.68,"",19.3,6,"46,XX[20]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]",176,"CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).",6.3,22.01,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",E54FS*28; MAF 44.0%,"","","","",A382FS*4; MAF 40.0%,""
16-00273,training,2595,Female,Female,White,3,n,62,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,62,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7,Dead,169,Dead-Disease,FALSE,FALSE,"",-2,,"","",,,,,,,"",,,,"",,,"46,XX[20]",,,Normal,,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",c.68dup; MAF 21%,"","","","","","",c.2645G>A; MAF 43.9%,"","","","","","","","","","","","","","","","","","","","","","","","",c.35G>A; MAF 30.2%,"","","","","","","","","","","","","","","","","","","","","","",c.1142C>A; MAF 36.4%,""
16-00278,training,2597,Male,Male,White,5,n,64,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,41,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,440,Alive,FALSE,FALSE,"",0,0,83,74,0,,13,0,13,,15,45,4,1.27,"",25.2,8.7,"46,XY[20]",,,Normal,39,Positive,6,53.3,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","",negative,"","","","","","",c.2645G>A; p.R882H,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
16-00289,training,2606,Female,Female,White,1,n,65,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,45,Standard Chemotherapy,Azacitidine,Consolidation,34,Dead,142,Dead-Disease,FALSE,FALSE,"",0,0,95,92.9,0,0.7,3.6,1.4,1.4,0.1,101,55,3.2,0.83,"",37,12.4,"46,XX[20]",697,95.1,normal,42,"CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive",6.3,166.91,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00292,leaderboard,2607,Female,Female,White,1,n,73,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,3,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,3,Dead,4,Dead-Disease,FALSE,FALSE,"",0,0,90,98.4,0,0,0.8,0,0.8,0.1,18,36,2.9,1.44,"",25.9,8.2,"46,XX[20]",,90.6,Normal,19,"CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO",7.7,122.89,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","",p.R326P; MAF 50%,"","","","","","","","",p.R140Q; MAF 40%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00303,leaderboard,2611,Female,Female,HispNative,5,n,56,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,56,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",4,Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,27,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Salvage,-1,Dead,323,Dead-Disease,FALSE,FALSE,"",0,0,1.5,2,0,,23,57,13,,67,33,3,1.87,"",29,9.5,"46,XX[19]",,,Normal,28,Positive,7.5,58.7,FALSE,FALSE,"",positive,positive,"",c.1954G>A; p.G652S,"","","","","","","","","","","",negative,"","","","","","",c.2644C>T; p.R882C,"","","","",c.2503G>T; p.D835Y,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
16-00315,training,1973,Male,Male,White,1,n,70,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,72,423,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Alive,523,Alive,TRUE,TRUE,15-00874,-142,0,"","",0,0,15.5,6.9,5.2,0,79,38,3.1,0.8,"",27.9,9.1,"47,XY,+4[2]/46,XY[18]",,87.7,"Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.",44,"",6.3,50.58,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00332,training,2621,Male,Male,White,6,n,72,FALSE,FALSE,FALSE,Unknown,TRUE,FALSE,y,Lung Cancer,y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",Adverse,Not Enough Information,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",73,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Vidaza,1,Supportive/Palliative Care,"","",,Standard Chemotherapy,Vidaza,Supportive/Palliative Care,268,Dead,292,Dead-Unknown,FALSE,FALSE,"",0,,"",4,1,,13,5,23,,13,57,2.5,1.83,"",25,8.2,"",,105.9,"",32,"",5.8,66.7,FALSE,FALSE,"",negative,negative,"",p.R693* MAF 48%,"","","","","","","","","","","","","","","","","","","","","",p.C565R MAF 27%,"","","","","","","","","p.V617F, MAF 26%","","","","","","p.Q61P, MAF 13%","","","","","","","","","","","","","","","","p.S322Nfs*277, MAF 42%","","","","","","","","","","p.Q866Rfs*14, MAF 39%","","","","","p.R295*, MAF 97%"
16-00339,training,2626,Female,Female,White,1,n,70,FALSE,FALSE,FALSE,None,TRUE,FALSE,n,"",n,n,n,n,n,n,y,n,MYELOPROLIFERATIVE NEOPLASMS,"Atypical chronic myeloid leukaemia, BCR-ABL1 negative",Intermediate,"",MYELOPROLIFERATIVE NEOPLASMS,"Atypical chronic myeloid leukaemia, BCR-ABL1 negative",70,0,Unknown,Bone Marrow Aspirate,y,y,y,y,y,y,1,Targeted Therapy - Kinase Inhibitor(s),1,Hydroxyurea,1,Induction,Unknown,Targeted Therapy - Kinase Inhibitor(s),-1,Targeted Therapy - Kinase Inhibitor(s),Hydroxyurea,Induction,-1,Alive,1,Alive,FALSE,FALSE,"",0,1.6,13,6.8,0.8,0,5.7,2.5,72.1,5.7,24,36,2.9,0.95,"",29.1,8.9,"46,XX[20]",953,105.1,Normal,208,"CD13, CD33, CD34, partial CD117, CD123, HLA-DR",6.7,109.77,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.N159S ; MAF 45%,"","","","","","","","","","","","","","","","","","","","","","","","","",p.K666N ; MAF 45%,"","","","","","","","","","","","",""
16-00344,training,2628,Male,Male,White,1,n,59,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,HiDAC,Consolidation,96,Alive,188,Alive,TRUE,FALSE,16-00345,0,0,30,10.5,0,0,19.7,0.9,71.4,0,77,27,3.4,1.01,"",26.4,8.9,"46,XY[20]",479,96.4,Normal,101,"CD13, CD33, CD117, CD123, and HLA-DR",6.4,4.4,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","",p.R882C; MAF 40%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.K70R; MAF 40%,"","","","","","",p.Q210H ; MAF 55%,"","","","","","","","","","",""
16-00351,leaderboard,2630,Female,Female,HispNative,1,y,46,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,46,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,120,Alive,192,Alive,FALSE,FALSE,"",-3,,"","",,,,,,,"",,,,"",,,"46,XX[20]",,,Normal,,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",p.T98fs*10 ; MAF 40%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Q758*; MAF 45%,"","","","",""
16-00354,training,2632,Male,Female;Male,White,3,n,79,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Unknown,,"",FALSE,FALSE,"",-1,,86,87,,,,,,,"",,,,"",,,"43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]",,,5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present,27,"",,70.01,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Asp816Val; MAF 44.4%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.?; MAF 91%,"","","",""
16-00356,training,2633,Male,Male,HispNative,6,n,59,FALSE,FALSE,TRUE,Unknown,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,59,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Lenalidomide|3+7 (Cytarabine, Daunorubicin)",2,Unknown|Supportive/Palliative Care,"","",,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Unknown,-1,Dead,207,Dead-Unknown,FALSE,FALSE,"",0,,"",1,9,,1,6,58,,135,44,3.2,0.79,"",21.6,7.3,"",,85,"",22,"",5.9,9.1,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","p.Q61H, MAF 21%","","","","","","","p.G273V ,MAF 64%","","","","","","","","","","","","","","","","",""
16-00392,training,2664,Female,Female,White,1,n,78,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,78,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,Ruxolitinib|Hydroxyurea|Decitabine,2,Consolidation|Experimental,"","",,Targeted Therapy - Kinase Inhibitor(s),Ruxolitinib,Experimental,7,Dead,24,Dead-Unknown,FALSE,FALSE,"",-1,0,"","",0,1.6,43.7,9.4,29.7,5.5,27,39,2,0.41,M7,26.2,8.2,"46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1]",1024,89.4,RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21).,17,"",5.5,6.28,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","",p.M1V; MAF 32%,"","","","","","","","","","","","","",p.S505N; MAF 70%,"","","","","","","","","","","","","","","","","","","","","","","",p.V636fs*3; MAF 46%,"","","","",""
16-00410,training,2678,Male,Male,White,1,n,62,FALSE,TRUE,FALSE,PML-RARA,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,62,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Induction,-1,Alive,320,Alive,FALSE,FALSE,"",0,0,90,53,0.9,3.5,35.7,1.7,5.2,0.7,28,24,2.8,1.12,M3,19.8,7,"46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20]",519,85.7,"PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype.",38,"CD13, CD33, CD38, CD58, CD64, dim CD71, CD123, CD117, MPO positive -FISH for t(15;17)",5.4,9.87,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00459,training,2687,Female,Female,HispNative,1,n,61,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea",4,Consolidation|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,7,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,55,Dead,263,Dead-Disease,FALSE,FALSE,"",0,0,"","",0,0,30.8,10.3,0,0.3,195,75,3.6,0.68,"",25.4,8.2,"",1033,95.5,"",49,"",6.7,73.28,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00465,leaderboard,2690,Male,Male,HispNative,1,n,12,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,12,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide",3,Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Intrathecal,0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Mismatched Unrelated Donor,-1,Alive,233,Alive,FALSE,FALSE,"",1,0,70,85,0,1.8,14.7,51.4,8.3,50,28,150,3.7,0.64,M4,14.3,4.6,"47,XY,+8[19]/46,XY[1]",,132.4,RUNX1T1 signal consistent with the trisomy 8 clone,49,"dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR",7.1,214.49,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00479,leaderboard,2697,Female,Female,White,3,n,39,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Leiomyosarcoma,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,40,0,Residual Disease|Post-Chemotherapy|Post-Transplant,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",5,Allogeneic - Sibling|Salvage|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,30,Standard Chemotherapy,Azacitidine,Salvage,4,Unknown,,"",FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11]",,,"",,"Increased atypical CD34 positive, CD7 positive myeloblasts",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00481,leaderboard,2699,Female,Female,White,3,n,60,FALSE,FALSE,FALSE,CBFB-MYH11,FALSE,FALSE,y,Adenocarcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,61,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|IDAC",2,Consolidation|Induction,UNKNOWN,Standard Chemotherapy,-1,Standard Chemotherapy,IDAC,Consolidation,-1,Dead,336,Dead-Disease,FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"46,XX,inv(16)(p13q22)[20]",,,"",,Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.,,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00483,training,2612,Male,Male,White,6,n,71,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,57,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Alive,402,Alive,FALSE,FALSE,"",0,,33,"",,,,8,,,"",,,,"",,,"46,XY,del(7)(q32),add(13)(p11.2)[20]",,,"Not Available. Pathogenic alterations are DETECTED in the ASXL1, IDH1, JAK2 and RUNX1 genes. Genomic alterations of uncertain significance are DETECTED in the CEBPA and TET2 genes (not seeing specific mutations or MAF)",22,"They are positive for CD34, HLADR, CD117, CD13 and MPO and negative for TDT.",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00494,training,2705,Female,Female,White,1,n,72,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,72,1,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Salvage,5,Dead,148,Dead-Disease,FALSE,FALSE,"",0,0,90,94,1.9,0,4.6,89.8,3.7,0.2,"",,2.8,0.93,M5,37.1,11.9,"46,XX,t(1;11)(p32;q23)[20]",,96.6,MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal,33,"dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive",,104.44,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","",p.E283*; MAF 30%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00498,training,2706,Female,Female,White,3,n,33,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,33,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,-1,Alive,468,Alive,FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"",,,This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.,26,"Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.",,12.75,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00504,training,2708,Female,Female,White,2,n,60,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,60,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,259,Dead-Disease,FALSE,FALSE,"",0,2,2,0,1,,12,12,71,,27,,4.4,0.99,"",33.5,11.4,"46,XX[20]",,95.4,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",219,The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia.,7.1,5.54,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","",R311Q; MAF 48%,"","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00510,leaderboard,2712,Male,Male,HispNative,1,n,34,FALSE,TRUE,FALSE,GATA2-MECOM,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,34,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine",3,Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),anti-CD33,Experimental,-1,Dead,291,Dead-Disease,FALSE,FALSE,"",0,0,60,28.9,0,2.1,44.3,8.2,16.5,5.5,117,61,3.9,1,"",35.6,11.7,"46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]",424,96,D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the metaphase karyotype.,916,"",7.7,6.13,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Q61H; MAF 45%,"","","","","","","","","","","","","","","","","","","","","","","",""
16-00519,training,2713,Male,Male,White,1,n,47,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,47,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Allogeneic - Sibling,-1,Alive,381,Alive,FALSE,FALSE,"",0,0,"",72.9,0,0,20.3,3.4,3.4,6.9,49,21,3.5,1.08,"",42.6,15,"46,XY[20]",353,86.8,Normal,34,"CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,",7.4,8.98,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",p.R35fs*125; MAF 50%,"","",p.P505L; VAF 45%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00525,training,2715,Female,Female,Asian,1,n,26,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,26,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Allogeneic - Mismatched Unrelated Donor,-1,Alive,352,Alive,FALSE,FALSE,"",0,0,95,40.2,0,0,45.5,9.8,4.5,0.2,32,58,3.1,0.69,"",22.3,7.4,"46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]",,97.8,"CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.",154,"CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+",5.8,9.27,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.D61G; MAF 15%,"","","","","","","","","","","","",p.S1039L; MAF 50%,"","","","",""
16-00538,leaderboard,2694,Male,Male,Black,6,n,50,FALSE,FALSE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,50,21,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Unknown,Standard Chemotherapy,20,Standard Chemotherapy,HiDAC,Consolidation,182,Alive,424,Alive,TRUE,TRUE,16-00474,-22,,8,0,0,,12,29,54,,19,9,2.3,0.51,"",22.8,7.5,"46,XY,t(8;21)(q22;q22)[20]",,88.7,RUNX1/RUNX1T1 fusion positive in 6.5% of cells,224,"",5.1,6.8,TRUE,TRUE,16-00474,negative,negative,"","p.P581R, MAF 46%","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","p.D111N, MAF 52%","","","","","","","","","","ASXL1, PDGFRB, SMC1A","","","","","","","","","","","",""
16-00540,training,2721,Female,Female,White,3,n,66,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",66,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,UNKNOWN,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Unknown,,"",FALSE,FALSE,"",0,,"",16,,,,,,,"",,,,"",,,"47,XX,+8[18]",,,Normal,,"Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML.",,129.5,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Val379fs; MAF 13%,p.Arg415Trp; MAF 48.9%
16-00547,training,2723,Male,Male,HispNative,1,n,29,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,29,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,19,Standard Chemotherapy,HiDAC,Re-induction,4,Dead,65,Dead-Unknown,FALSE,FALSE,"",0,0.9,82,20,0,2.6,26.3,33.4,7.9,3.6,40,19,3.1,0.84,"",27.3,9.1,"46,XY,t(9;11)(p22;q23)[20]",324,89.5,"94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype.",52,"CD11b, varibleCD13, CD14, brightCD33, CD64, and HLA-DR positive",6.7,3.88,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00548,training,2119,Male,Male,White,1,n,76,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,417,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,35,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Induction,77,Dead,520,Dead-Unknown,TRUE,FALSE,16-00557,6,0,"","",0.9,,60.3,38.5,0.3,,19,19,3.2,1,"",24.2,8.6,"47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]",261,102.5,"Eighteen of twenty-one cells examined were trisomy 8, previously observed.Two of these cells also had an extra 1q attached to a chromosome 21 short arm, and two other cells had an extra 1q attached to a chromosome 22 short arm. These are new clonal changes. One cell appeared normal male.",7,"",7.2,3.4,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00564,training,2740,Female,Female,White,6,n,81,FALSE,FALSE,FALSE,None,TRUE,FALSE,y,Rectal Cancer,y,y,n,n,y,n,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Adverse,Adverse,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,81,0,Unknown,Bone Marrow Aspirate,y,y,y,n,y,y,1,Other,1,Radiation,1,Unknown,"","",,Other,Radiation,Unknown,22,Alive,0,Alive,FALSE,FALSE,"",0,,5,0,,,,2,,,"",,,,"",,,"45,X,-X,del(9)(q13)[12]/46,sl,i(X)(q10)[8]",,,9q deletion is present in all metaphase cells analyzed. All cells have also show either missing one X chromosome or an isochromosome for its long arm. It is most likely that the X chromosome abnormalities represent constitutional changes associated with Turner syndrome.,30,Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alteration is detected in the TET2 gene. Genomic alterations of uncertain significance are detected in the EZH2 and NF1 genes.,,35.1,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","p.L128S ,MAF 49%","",negative,"","","","","","","","","","",negative,"","","","","","","p.F2388I, MAF 45%","","","","","","","","","","","","","","","","","","","","","p.R1452*, MAF 98%","","","","",""
16-00627,leaderboard,2785,Male,Male,White,7,n,67,FALSE,FALSE,FALSE,Unknown,TRUE,FALSE,n,"",y,n,n,n,n,n,y,y,MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Adverse,Not Enough Information,MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,66,0,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Cytarabine|Decitabine,2,Induction|Supportive/Palliative Care,UNKNOWN,Standard Chemotherapy,-1,Standard Chemotherapy,Cytarabine,Induction,-1,Unknown,,"",FALSE,FALSE,"",0,,17,7,,,,,,,"",,,,"",,,"",,,Trisomy 8,,"",,,FALSE,FALSE,"",negative,negative,"",positive,"","","","","","","","","","","","","","","","","","","","","",positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","",positive,"","",positive,"","","","","",positive,"","","","","","","","",""
16-00699,training,3975,Male,Male,HispNative,2,n,46,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",46,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Dead,9,Dead-Treatment,FALSE,FALSE,"",0,,92,75,,,5,19,1,,"",,2.8,1.13,"",18.4,6.2,"46,XY[20]",,113.6,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",31,"CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), TdT(partial dim+)",,151.6,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00701,training,2747,Male,Male,White,6,n,62,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,y,n,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,62,34,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,n,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Azacitidine|Fludarabine, Melphalan, ATG",2,Unknown|Allogeneic - Matched Unrelated Donor,"","",,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1,Alive,256,Alive,TRUE,FALSE,16-00578,-34,,"",1,0,,22,28,42,,37,29,4.7,1.03,"",38.2,12.4,"46, XY [20]",,91,The abnormalities normally seen in MDS are not detected.,237,"",7.8,16.4,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00702,training,3976,Male,Male,White,7,n,77,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,79,0,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Induction,-1,Unknown,,"",FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"",,,Translocation between the long arm of chromosome 3 and short arm of chromosome 12.,,"",,,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00705,leaderboard,3978,Male,Male,White,5,n,59,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,0,Relapse,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI ",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,1824,Dead-Disease,FALSE,FALSE,"",0,0,59.5,12,0,,55,3,29,,37,22,4.1,,"",25.2,8.3,"47,XY,+13[2]/94,slx2[2]/46,XY[19]",,,"5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter)",46,Negative,6.4,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00708,training,3979,Male,Male,HispNative,2,n,70,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Azacitidine|Decitabine,1,Hypomethylating/Low Dose Cytarabine,"","",,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,98,Unknown,,"",FALSE,FALSE,"",0,0,44,31,2,,46,0,14,,41,18,3.7,0.91,"",21.6,7.1,"47,XY,+21[19]/46,XY[1]",91,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],",35,"CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly + and variable), TdT(partial +), and MPO(-)",7.7,5.05,FALSE,FALSE,"",positive,negative,"","","","",Foundation; R1480*; MAFs: 88%,Foundation; P304fs*117; MAFs: 72%,"","","","","","","","","","","","","","",Foundation; R882H; MAFs: 44%,"","","","",negative,"","",negative,negative,"","","","","","","","","","","","","",Foundation; I679fs*21; MAFs: 5%,"","","","",Foundation; R225*; MAFs: 87%,"","",Foundation; A72T; MAFs: 8%,"","",Foundation; I366fs*114+; MAFs: 57%,"","","","","","","","","",Foundation; Q742*; MAFs: 41%,"","","","",""
16-00710,leaderboard,2694,Male,Male,Black,6,n,50,FALSE,FALSE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,50,73,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Unknown,Standard Chemotherapy,20,Standard Chemotherapy,HiDAC,Consolidation,182,Alive,424,Alive,FALSE,FALSE,"",0,,0,"",,,,0,,,"",,,,"",,,"46,XY[20]",,,RUNX1/RUNX1T1 fusion negative,126,No morphological evidence of acute leukemia,,7.7,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00724,training,3986,Female,Female,White,2,n,62,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,7,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,198,Dead-Disease,FALSE,FALSE,"",0,0.8,34,3.3,1.6,,14.9,5,68.6,,13,11,2.6,0.5,"",32.4,10.7,"46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11,+14[",304,,"nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",36,"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +).",5.3,8.35,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","",negative,negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","",R213fs; MAF 34%,"","","",""
16-00731,training,3990,Female,Female,White,1,n,69,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",69,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,7,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Midostaurin|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6,Targeted Therapy - Other,ALRN-6924,Salvage,-1,Alive,442,Alive,FALSE,FALSE,"",0,1.8,40,42.1,0.9,8.8,10.5,9.6,26.3,2.8,27,22,3.4,0.64,"",23.5,7.1,"46,XX[20]",399,103.5,normal,12,"CD13, CD34, CD58, CD117, partial MPO and HLA-DR +",6.5,61.22,FALSE,FALSE,"",positive,negative,"","","","","","","","","","","","","","","","",p.S893L; MAF 41%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.A187T; MAF 42%,"",p.K700E; MAF 51%,"","","","","","","",p.K751fs*61; MAF 44%,"","","","",""
16-00733,training,2119,Male,Male,White,1,n,76,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,472,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,35,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Induction,77,Dead,520,Dead-Unknown,TRUE,FALSE,16-00732,0,0,54,13,6.9,,51.6,39.6,1.9,,20,23,3.2,1,"",25.4,8.6,"47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]",,92,"Seventeen of twenty cells examined were trisomy 8, previously observed.Two of the trisomy 8 cells had additional non-clonal abnormalities and two cells had an extra 1q attached to a chromosome 22 short arm, also previously observed.",22,"The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR positive. Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without  aberrant antigen expression.",7.2,4.5,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00766,training,4006,Male,Male,White,2,n,81,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",n,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,81,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Vidaza|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,"","",,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,3,Dead,97,Dead-Disease,FALSE,FALSE,"",-32,,33,8,4,,28,24,44,,22,20,4.1,1.07,"",27.5,9.5,"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]",333,,"nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5’CBFB con 3’CBFB dimx1,5’CBFB con 3’CBFBx1)[200]",28,"CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-), TdT(-).",6.6,2.2,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","",Foundation; EP300-ZNF205 fusion; MAFs: N/A,"","","",negative,"","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",Foundation; L206fs*41; MAFs: 31%,"","","",""
16-00770,training,4007,Female,Female,White,6,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,51,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib",3,Unknown|Induction|Re-induction,Unknown,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Unknown,-1,Alive,555,Alive,FALSE,FALSE,"",0,,12,"",,,,17,,,"",,,,"",,,"46,XX[20]",,,"",16,"FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO.",,1.5,FALSE,FALSE,"",negative,negative,"","","","","p.E1348Ifs, MAF 32%","","","","","","","","","","","","","","","","","","","","",negative,"","","","p.R172K, MAF 41%","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","p.T171Cfs*116, MAF 39%",""
16-00771,leaderboard,4008,Female,Female,HispNative,6,n,34,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia,34,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,3,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone",3,Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,35,Intrathecal,Cytarabine,Unknown,6,Dead,157,Dead-Unknown,FALSE,FALSE,"",0,,15,"",,,,12,,,"",,,,"",,,"46,XX[20]",,,"",426,"",,26.4,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","p.A470V, MAF 51%","","","p.R882C, MAF 51%","","","","",negative,"","","","","","","","","","",negative,"","","","","","","","","p.G13R, MAF 48%","","","","","","","","","","","","","","","","","","","","p.R282Q, MAF 51%","","","",""
16-00810,training,4028,Female,Female,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Alive,189,Alive,FALSE,FALSE,"",0,0,83,11.5,1.8,1.8,13.3,63.7,7.9,0.1,69,35,3,0.87,M5,34.7,11.6,"46,XX[20]",337,95.6,Normal,146,Positive,6.1,44.83,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.R132H; MAF 37%,"","","","","","","","","","","","","","","","",p.G13D; MAF 38%,"","","","","","","","","","","","","","","","","","","","","","","",""
16-00815,leaderboard,4030,Female,Female,White,1,n,60,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea",4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Complete Response,Standard Chemotherapy,18,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Alive,197,Alive,FALSE,FALSE,"",-1,0,75,44,0,0.9,28.7,46.1,24.3,0,18,13,2.9,1.19,M5,26.4,8.8,"46,XX[20]",222,96.4,Normal,175,Positive,6.9,34.6,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","",p.T15_G16insP; MAF 48%,"","","","","","","","","","","","","","","","","","","","",p.G12S; MAF 40%,"","","","","","","","","","","","","","","","","","",p.H437fs*7; MAF 42%,"","","","",""
16-00818,leaderboard,4029,Female,Female,White,3,n,65,FALSE,FALSE,TRUE,GATA2-MECOM,FALSE,FALSE,n,"",n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,65,3,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Unknown,,"",TRUE,FALSE,16-00813,-3,,"","",,,,,,,"",,,,"",,,"47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]",,,evidence of monosomy 7 in 191/200 (95.5 percent) cells scored,,"",,,TRUE,FALSE,16-00813,negative,negative,"","","","","","","","",p.Leu367fs; MAF 24%,p.? ; MAF 16.5%,"","","","","","","","","","",p.Ala571Pro; MAF 51.5%,"","",p.Pro636Ala; MAF 94.7%,"",p.Val579Ala; MAF 2.3 %,"","","","","","","","","","","","","","","","","","","","","","","","","",p.Gly60Ser; MAF 49.1%,"","",p.Asp198Gly; MAF 63.7%,"","","","","","","","","","","","","","",""
16-00822,training,2747,Male,Male,White,6,n,62,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,y,n,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,62,81,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Azacitidine|Fludarabine, Melphalan, ATG",2,Unknown|Allogeneic - Matched Unrelated Donor,"","",,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1,Alive,256,Alive,TRUE,FALSE,16-00578,0,,9,"",,,,7,,,"",,,,"",,,"46,XY[12]",,,The abnormalities normally seen in MDS are not detected.,,A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent blasts.,,,TRUE,TRUE,16-00701,negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00831,training,4038,Male,Male,Black,2,n,73,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",77,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Supportive/Palliative Care|Targeted Therapy - Other,6,Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine,3,Hypomethylating/Low Dose Cytarabine|Experimental|Supportive/Palliative Care,"","",,Targeted Therapy - Other,AG-221,Experimental,267,Dead,1490,Dead-Disease,FALSE,FALSE,"",0,,95,48,1,,42,6,2,,14,14,3.5,1.1,"",27.3,9.4,"88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]",453,,"nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]",23,"92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(partial +).",6.5,3,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,"R140Q (c.419G>A, p.Arg140Gln)","","","","","","","","","","","","","","","","","","","","","",E76Q,"","",loss,"","","","","","","","","","","","","","",""
16-00836,leaderboard,4039,Male,Male,White,1,n,73,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea",1,Induction,Refractory,Standard Chemotherapy,167,Standard Chemotherapy,"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)",Induction,21,Dead,28,Dead-Disease,FALSE,FALSE,"",0,0,88,38,0,1.7,20.9,60.9,1.7,0.1,27,40,3,1.2,"",33,11.2,"46,XY[20]",,105.8,normal,55,Positive,7.5,58.97,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","",p.R882H; MAF 42%,p.N674D; MAF 50%,"","","","","","","","","","","","","","","",p.M3398V; MAF 51%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00867,training,4042,Female,Female,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,3,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Hydroxyurea,1,Induction,Unknown,Standard Chemotherapy,8,Standard Chemotherapy,Hydroxyurea,Induction,8,Dead,8,Dead-Unknown,FALSE,FALSE,"",-5,0,93,85,0.8,0,16.5,0.8,1.6,0.2,19,21,2.7,0.78,"",21.1,7.1,"46,XX[20]",360,84.4,Normal,43,"partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO",5.7,30.54,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.R140Q; MAF ~50%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00882,training,4006,Male,Male,White,2,n,81,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",n,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,81,41,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Vidaza|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,"","",,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,3,Dead,97,Dead-Disease,TRUE,TRUE,16-00766,-73,0,"",70,0,,3,1,36,,25,33,4.1,1.26,"",24.1,8.1,"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]",853,98,"nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5’CBFB con 3’CBFB dimx1,5’CBFB con 3’CBFBx1)[200]",74,negative,,39.12,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-00951,training,4075,Male,Male,White,3,n,42,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,42,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",4,Allogeneic - Sibling|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Alive,223,Alive,FALSE,FALSE,"",-3,,"","",,,,,,,"",,,,"",,,"45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]",,,11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored,,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01004,training,4195,Male,Male,White,2,n,70,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,70,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Vidaza,Hypomethylating/Low Dose Cytarabine,4,Alive,95,Alive,FALSE,FALSE,"",0,0,85,77.8,0,,7.4,0,11.1,,12,32,2.8,0.62,"",21.8,7,"",1195,,"",103,"",5.2,25.85,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01005,training,4196,Female,Female,White,5,n,55,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,153,Alive,FALSE,FALSE,"",0,1,30,0,0,,31,4,6.8,,10,11,4.3,,"",32.4,9.9,"46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]",,,Probe: 8 centromere/20q12,83,Negative,7.2,10.6,FALSE,FALSE,"",negative,negative,"",c.190 0_1922 delAGAGAGGCGGCCACCACTGCCAT; p.R634Rfs; MAF 33%,"","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,c.419G>A; P.R140Q; MAF 46%,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
16-01010,training,4197,Female,Female,White,1,n,45,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32,Standard Chemotherapy,Sunitinib,Consolidation,2,Dead,634,Dead-Disease,TRUE,FALSE,16-01104,0,0,"","",0,0,20.4,0,66.7,1,58,44,3.3,1.04,"",23.8,8.1,"",401,88.5,Positive,14,"",7.3,6.18,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01017,training,4043,Male,Male,AdmixedHispNative,6,n,25,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",26,28,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Unknown|Induction,Complete Response,Standard Chemotherapy,79,Standard Chemotherapy,Bu/Cy/ATG,Unknown,22,Alive,444,Alive,FALSE,FALSE,"",0,,70,8,,,,4,,,"",,,,"",,,"46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]",,,"",10,"MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR ",,30.2,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.S2496C; MAF 45%,"",p.Q61K; MAF45%,"","","","","","","","","","","","","","","","","","","","","","","",""
16-01049,training,4207,Male,Male,Asian,2,n,78,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",78,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine",4,Induction|Re-induction|Maintenance|Supportive/Palliative Care,Refractory,Supportive/Palliative Care,-1,Standard Chemotherapy,"Etoposide, Cytarabine",Supportive/Palliative Care,-1,Dead,372,Dead-Disease,FALSE,FALSE,"",0,0,20,3.8,7.8,,40,5.2,40,,9,49,3.1,1.41,"",25.7,8.5,"46,XY[20]",675,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",30,"CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-).",6.9,4.9,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01061,leaderboard,4197,Female,Female,White,1,n,45,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,14,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32,Standard Chemotherapy,Sunitinib,Consolidation,2,Dead,634,Dead-Disease,TRUE,FALSE,16-01104,0,,"","",,,,,,,"",,,,"",,,"",,,Positive,,"",,,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01093,training,4229,Male,Male,White,2,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,"",0,"",0,"","","",,NONE,NONE,NONE,,Unknown,,"",FALSE,FALSE,"",0,0,48,6,0,,31,14,47,,27,27,4.2,0.86,"",36.9,12.6,"47,XY,t(8;19)(q24.1;q13.1),+10[17]/46,XY[3]",294,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",175,"",7,2.43,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01094,training,2254,Female,Female,White,2,n,52,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",53,462,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1,Dead,633,Dead-Disease,TRUE,TRUE,15-00653,-463,,76,1,,,,,,,"",,,,"",,,"46,XX[20]",,,"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01097,training,2116,Female,Female,White,1,n,10,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,12,568,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,33,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Re-induction,-1,Alive,569,Alive,FALSE,FALSE,"",0,0,46,"",0,0,81.3,8.3,10.4,18.1,31,27,3.8,0.53,"",30.5,10.2,"47,XX,+10[19]/46,XX[1]",,96.8,Normal,11,"variable CD7,  dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive",7,1.93,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01100,training,4231,Male,Male,White,2,n,65,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Cytarabine,1,Supportive/Palliative Care,"","",,Standard Chemotherapy,Cytarabine,Supportive/Palliative Care,-1,Dead,2,Dead-Unknown,FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"",,,"nuc ish (PML,RARA)x2[199]",,"",,,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01102,training,4232,Female,Female,White,2,n,72,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,"","",,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Alive,358,Alive,FALSE,FALSE,"",0,,30,5,,,,,,,37,93,,,"",,,"45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]",,,"nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[200]",16,"",,44.63,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01103,training,4197,Female,Female,White,1,n,45,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,23,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32,Standard Chemotherapy,Sunitinib,Consolidation,2,Dead,634,Dead-Disease,TRUE,FALSE,16-01104,0,0,90,90,0,0,5,0,0,0,27,43,1.6,0.93,"",22.5,7.9,"",,82.1,Positive,43,"variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive",5.1,18.38,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01109,leaderboard,4235,Male,Male,Black,5,n,33,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,33,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,116,Alive,TRUE,FALSE,16-01108,0,0,72,95,0,,3,0,1,,29,24,3.4,,"",19.8,6.5,"46,XY,inv(16)(p13.1q22)[20]",,,Positive for CBFB rearrangment for 91% of cells,31,Positive,6.6,93.2,TRUE,FALSE,16-01108,negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","","",negative,"","","","","","","","","","","","","","","","","","",c.652G>A; p.V218M; MAF 50%,negative,"","","",""
16-01121,training,4239,Male,Male,White,3,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Matched Unrelated Donor,-1,Alive,184,Alive,FALSE,FALSE,"",0,,86,89,,,,,,,"",,,,"",,,"46,XY[20]",,,Normal,57,"",,115.15,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","","","","","","","","",p.Arg326Cys; MAF 44.5%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",p.Ala911fs; MAF 40.6%,"","","","",""
16-01127,leaderboard,2538,Male,Male,White,1,n,67,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,261,Post-Chemotherapy,Leukapheresis,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,4,"AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,-1,Alive,528,Alive,TRUE,TRUE,16-00157,-52,,"","",,,,,,,"",,,,"",,,"46,XY[20]",,,Normal,,"",,,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01138,training,2315,Male,Male,White,1,n,62,TRUE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,412,Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,Decitabine|Hydroxyurea,2,Induction|Re-induction,Complete Response i,Standard Chemotherapy,-1,Standard Chemotherapy,Hydroxyurea,Re-induction,-1,Dead,424,Dead-Disease,TRUE,TRUE,15-00778,-412,0.9,"","",0,0,7.8,1.7,4.3,0.1,18,21,2.8,1.43,"",25,8.2,"46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]",564,102.5,EGR1 (73.5%) ;  TP53: (85.5%),139,"",6.6,46.79,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01151,training,4248,Male,Male,White,1,n,81,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,81,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Vidaza, BI836858 (anti-CD33)",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Vidaza, BI836858 (anti-CD33)",Induction,-1,Alive,355,Alive,TRUE,FALSE,16-01150,0,0,"",80,0,7,7.8,0,6.9,0.5,31,42,3.2,1.3,"",25.1,8.8,"46,XY[19]",665,85.1,Normal,16,"dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive",7.2,33.81,TRUE,FALSE,16-01150,negative,positive,"","","","","","","","","","","","","",negative,"","","",p.T640N; MAF: 14%,"","",negative,"","",p.G709D; MAF: 17%,"",negative,"","",negative,p.R140Q; MAF: 46%,"","",negative,"",Splice site-Intron 5 3' end mutation; MAF:3%,negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
16-01185,leaderboard,4252,Male,Male,White,5,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,50,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,201,Dead-Unknown,FALSE,FALSE,"",0,0,75,82,2,,4,0,8,,39,45,3.7,,"",20.1,6.5,"46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20] ",,,Loss of 5q31 sequences for 99% of total cells,12,"Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR",6.3,119.6,FALSE,FALSE,"",positive,negative,"","","","",C.3067T>C; p.F1023L,"","","","","","","","",negative,"","","","","","",negative,"","","","","","","",negative,negative,"","",negative,"","",negative,"","",negative,"","","","","",c.7625G>A; p.S2542N,negative,"","","","","","","","","","","","","","","","","","","",negative,"","","",""
16-01191,training,4256,Female,Female,White,3,n,65,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,65,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)",3,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,246,Alive,TRUE,FALSE,16-01190,0,,"","",,,,,,,"",,,,"",,,"45,XX,-7[20]",,,"7cen (D7Z1), 7q31 (D7S486): monosomy present ",,"",,,TRUE,FALSE,16-01190,negative,negative,"","","","","","","","","","","","","","","","","","","","",p.Gln231fs; MAF 33.2%,"","","","","","","","",p.Arg140Gln; MAF 44.2%,"","","","","","","","","","","","","","","",p.Gln61Glu; MAF 47.8%,"","","","","","","","","","","","","","","","","","","","","","","",""
16-01192,leaderboard,4201,Female,Female,White,1,n,52,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,52,34,Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"MiDAC|FLAG-IDA plus Midostaurin|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,FLAG-IDA plus Midostaurin,Salvage,-1,Alive,414,Alive,TRUE,TRUE,16-01143;16-01022,-6,1.4,"","",0.2,,9.2,24.3,64.9,,119,151,3.2,0.76,"",28.4,9.2,"46,XX[20] ",380,93.4,Normal,395,"",6.6,6.5,TRUE,FALSE,16-01143;16-01146,negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",p.R882C; MAF 14%,"","","","",negative,"","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
16-01201,training,4260,Male,Male,White,1,n,53,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",54,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,7,"AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)",5,Salvage|Induction|Experimental|Re-induction|Maintenance,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Salvage,-1,Dead,543,Dead-Disease,FALSE,FALSE,"",0,0,75,90,0,0,22.1,6.2,1.8,0,19,33,1.8,0.84,"",25.5,8.1,"46,XY,t(4;12)(q12;p13)[10]/46,XY[10] ",706,91.4,"42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement.  Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4.  Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML",25,"partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive ",6.6,118,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",p.R882H; MAF 49%,"","","","",negative,"","",p.R132S; MAF 48%,negative,"","",negative,"","","","","",negative,"",negative,"","","","",negative,"","","","","","","","",p.R166*; MAF 50%,"","","","",p.P95H; MAF 50%,"","","","","",negative,"","",negative,""
16-01216,training,4263,Male,Male,White,3,n,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,1,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC",3,Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Child,-1,Alive,395,Alive,TRUE,TRUE,16-01210,-18,,"","",,,,,,,"",,,,"",,,"46,XY[11] ",,,Normal,,"",,,TRUE,TRUE,16-01210,negative,negative,"","","","",p.Tyr354*; MAF 72.2%,"","","","","","","","","","","","","","","",p.Thr835Met; MAF 47%,"","","","","","","",p.Arg132Cys; MAF 2.9%,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01219,training,4271,Male,Male,White,1,y,47,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,47,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,317,Alive,FALSE,FALSE,"",0,0,83,82,3.4,0,23.1,3.4,0,1.6,23,11,3.5,0.95,"",31.1,10.2,"46,XY[20]",290,88.9,"",24,"CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO ",6.5,18.71,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",p.I68fs; MAF 50%,"","","","","","",negative,"","",p.S519P; MAF 51%,"",negative,"","",negative,negative,"","",negative,"","",negative,"","","","",negative,"","","","","p.G13D, MAF 3%","","","","","","","","",negative,"","","","","","","","","","",negative,"","",p.R458*; MAF 23%,""
16-01223,training,4273,Male,Male,White,2,n,73,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",73,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,"","",,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Dead,31,Dead-Unknown,FALSE,FALSE,"",0,,83,59,,,,,,,21,23,,,"",,,"46,XY[20]",,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",22,"",,24.23,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01225,training,4274,Female,Female,White,1,n,61,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,"",n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Hydroxyurea,1,Supportive/Palliative Care,"","",,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,316,Dead-Disease,FALSE,FALSE,"",-2,,"","",,,,,,,"",,,,"",,,"46,XX[20]",,,Normal,,"",,,FALSE,FALSE,"",positive,positive,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","","","","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
16-01227,leaderboard,4275,Female,Female,HispNative,6,n,39,TRUE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,40,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,39,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,399,Alive,FALSE,FALSE,"",0,,"",91,,,9,,,,21,34,3.8,0.49,"",29.3,9.9,"",,93.6,"",66,"",5.8,73,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01237,training,4291,Female,Female,HispNative,6,n,73,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,"","",,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Alive,122,Alive,TRUE,FALSE,16-01238,0,,71,3,1,,68,8,11,,11,23,2.9,0.51,"",24.9,7.8,"46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]",,110.7,Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.,95,"blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and  negative for cd11b, cd14, cd64, tdt and mpo.",4.8,63.4,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","",negative,"","","","","","","","","","",negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
16-01254,training,4299,Female,Female,White,1,n,38,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,38,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,303,Alive,FALSE,FALSE,"",0,,47,21.7,,,,,,,"",,,,"",,,"46,XX[20]",,,Normal,,"CD117, dimCD4,  heterogeneous CD13, CD33, dimCD64 and  MPO positive ",,46.27,FALSE,FALSE,"",negative,positive,"","","","","","","","","","","","","",negative,"","","","","","",p.R882H; MAF 46%,"","","","",negative,"","",p.R132H; MAF 25%,negative,"","",negative,"","",negative,"","",p.Q61L; MAF 10%,"",negative,"","","","",p.G13D; MAF 24%,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
16-01262,training,4303,Female,Female,White,1,n,59,FALSE,TRUE,FALSE,PML-RARA,FALSE,FALSE,n,"",y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,59,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide, Idarubicin",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"ATRA, Arsenic Trioxide, Idarubicin",Induction,-1,Alive,28,Alive,FALSE,FALSE,"",0,0.9,90,90,1.7,44,8.6,0,6,1.5,110,255,2.4,0.86,M3,19.8,6.7,"46,XX,t(15;17)(q22;q21)[20]",,88.4,86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis.,30,"CD13, CD33, CD58, CD64, CD117, CD123, MPO",5.4,47.35,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","",negative,"","","","","","",negative,"","","","","","","",negative,negative,"","",negative,"","",negative,"","",negative,"",negative,"","","","",negative,"","","","","","","","",negative,"","","","","","","","","","",negative,"","",negative,""
16-01270,training,4317,Female,Female,White,1,n,72,TRUE,FALSE,FALSE,Unknown,FALSE,FALSE,n,"",n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,74,0,Relapse,Peripheral Blood,y,y,y,y,y,y,1,Targeted Therapy - Kinase Inhibitor(s),1,Dasatinib,1,Experimental,"","",,Targeted Therapy - Kinase Inhibitor(s),Dasatinib,Experimental,16,Unknown,,"",FALSE,FALSE,"",0,,"","",,,,,,,"",,,,"",,,"",,,"",,"",,,FALSE,FALSE,"",negative,negative,"","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
17-00066,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00111,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00113,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00123,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00177,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00185,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00195,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00210,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00230,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00248,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00252,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00262,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00264,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00276,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00287,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00300,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00304,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00313,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00322,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00325,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00328,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00337,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00346,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00360,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00423,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00436,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00438,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00441,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00442,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00444,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00446,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00452,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00464,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00467,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00478,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00482,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00485,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00491,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00499,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00514,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00551,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00556,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00613,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00634,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00641,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00676,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00678,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00685,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00687,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00690,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00694,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00741,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00755,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00770,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00776,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00779,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00843,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00851,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00862,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00867,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00878,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00881,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00901,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00908,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17-00915,validation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
